Comparison of flavonoid profile and respiratory smooth muscle relaxant effects of Artemisia afra versus Leonotis leonurus by Tikiso, Tjokosela
i 
 
 
Comparison of flavonoid profile and respiratory smooth muscle relaxant 
effects of Artemisia afra versus Leonotis leonurus. 
 
 
 
Tjokosela Tikiso 
 
 
 
A thesis submitted in fulfilment of the requirements for the degree of Magister Scientiae 
(Pharmaceutical Sciences) in the Discipline of Pharmacology at the University of the Western 
Cape, Bellville, South Africa. 
 
 
 
Supervisor: Prof. James Syce 
                                                    Co-supervisor: Dr Kenechukwu  Obikeze 
 
 
September 2015 
 
 
 
 
 
 
 
ii 
 
Comparison of flavonoid profile and respiratory smooth muscle relaxant effects 
of Artemisia afra versus Leonotis leonurus. 
 
 
 
 
Tjokosela Tikiso 
 
 
 
 
 
Key words 
Artemisia afra 
Leonotis leonurus 
Freeze dried aqueous extract 
Trachea smooth muscle relaxant 
Isolated guinea-pig trachea 
Flavonoids 
Luteolin 
HPLC 
  
 
 
 
 
iii 
 
 
Summary 
 
Leonotis leonurus (L. leonurus) and Artemisia afra (A. afra) are two of the most commonly 
used medicinal plants in South Africa traditionally advocated for use in asthma. However, 
proper scientific studies to validate these claimed uses are lacking and little is known about 
the mechanisms for this effect. These plants contain flavonoids, which are reported to have 
smooth muscle relaxant activity and may be responsible for the activity of these two plants. 
 
The objectives of this study were to: (1) determine and compare the flavonoid profiles and 
levels in A. afra and L. leonurus, (2) compare the respiratory smooth muscle relaxant effects 
of freeze-dried aqueous extracts of A. afra and L. leonurus and (3) investigate whether K
+
 - 
channel activation (i.e. KATP channel) is one possible mechanism of action that can explain 
the effect obtained in traditional use of these two plants. It was hypothesized that: (1) the 
flavonoid levels and profile of A. afra would be greater than the flavonoid levels and profile 
of L. leonurus, (2) A. afra would have a more potent respiratory muscle relaxant effect than 
L. leonurus and (3) A. afra and L. leonurus will inhibit K
+
 - induced contractions in a superior 
manner than carbachol and histamine - induced contractions.  
To realize these objectives, freeze-dried aqueous extracts (FDAE) of the dried leaves of the 
two plants were prepared. A validated HPLC assay was developed and used to identify and 
determine the levels of luteolin in the plant preparations. Solutions of the plant extracts were 
studied in the isolated guinea-pig trachea tissue preparation in the presence of carbachol, 
histamine and KCL. The possible mechanism of action of the two plants was determined by 
cumulative log dose-response curves (LDRC) for carbachol, histamine and KCL in the 
absence and presence of 1, 30 and 100 mg/ml solutions of the plant extracts.  
 
The flavonoid profile of un-hydrolyzed and hydrolyzed L. leonurus was greater than that of 
un-hydrolyzed and hydrolyzed A. afra. The levels of free and total luteolin in A. afra FDAE 
(8.977 ± 0.73 µg/ml and 16.394 ± 0.884 µg/ml, respectively) were significantly (p < 0.001) 
higher than that in L. leonurus FDAE (0.929 ± 0.066 µg/ml and 3.093 ± 0.531 µg/ml, 
respectively). L. leonurus and A. afra relaxed tracheal smooth muscles contracted with 
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histamine, KCL and carbachol in a dose dependent manner. The degree of relaxant activity of 
L. leonurus versus the three inducers of contraction (agonists) could be classified as KCL > 
carbachol > histamine, with EC50 values of 9.87, 29.34 and 94.76 mg/ml, respectively. The A. 
afra tracheal smooth muscle relaxant activity was categorized as carbachol > histamine > 
KCL, with EC50 values of 13.93, 15.47 and 19.88 mg/ml, respectively. Overall, A. afra which 
contained the higher levels of luteolin, was more potent at relaxing the guinea pig tracheal 
smooth muscle than L. leonurus.  
Collectively, the results confirm that aqueous solutions of A. afra and L. leonurus as used in 
local traditional practice have potent but different degrees of bronchodilator activities that 
could be useful in the treatment of asthma, and that these actions may be related to each 
plant‟s luteolin (or flavonoid) levels. Moreover it is very unlikely that KATP channels are 
primarily responsible for the actions of A. afra and L. leonurus, but rather that more than one 
mechanism of action is involved in the tracheal smooth muscle relaxant effects of these two 
plants. 
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Chapter 1 
Introduction 
 
Asthma is a chronic inflammatory condition of the airway which leads to hyper-secretion of 
the mucus glands, bronchoconstriction, and increased hyper-responsiveness of the airways, 
with involvement of many cells in particular mast cells, eosinophils and T lymphocytes. This 
chronic inflammation leads to recurrent episodes of breathlessness, reversible airflow 
obstruction, wheezing, chest tightness and coughing, particularly at night or in the early 
morning (GINA, 2015). It is estimated to affect over 300 million individuals worldwide, with 
approximately 250,000 annual deaths (Bousquet et al., 2000; Silva et al., 2015). South Africa 
is ranked 25th in the world in the prevalence of asthma, estimated to affect 8.1 % of the 
population. Shockingly, it was ranked fourth in highest asthma death rate in the World among 
5 to 35-year-olds in 2012 (Bateman et al., 2008). It is estimated that the number of 
individuals with asthma worldwide will increase by more than 100 million by the year 2025 
(Masoli et al., 2004). 
Current asthma treatment involves the usage of compounds such as corticosteroid anti-
inflammatories, β2 - adrenoceptor agonists, anti-leukotrienes, and anti-cholinergics (Rang and 
Dale, 2003). Despite the availability (and widespread use) of these anti-asthmatic drugs, the 
substantial economic load associated with disease control and morbidity continues to 
intensify. Moreover, the anti-asthmatic drugs do not always give the required therapeutic 
outcome (Barnes, 2012). They do not appear to modify the course of the disease significantly, 
and they are not curative (Barnes, 2012). Asthma symptoms and inflammation rapidly recur 
when the treatment is discontinued. All currently available inhaled corticosteroids are 
absorbed from the lungs and thus have the potential for systemic side effects (Barnes, 2012). 
There is thus a strong need for additional therapies especially alternative treatment such as 
herbal medicines to be explored.  
Traditional medicine in particular herbal medicine is a commonly practiced form of medicine 
in Africa with an estimated usage by 80 % of the population (WHO, 2002). About 27 million 
South Africans rely on traditional herbal medicine as a source of health, and because the use 
of herbal medicine forms a fundamental part of South African culture, this reliance on herbal 
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medicine is unlikely to change (Fennell et al., 2004). Medicinal plants are also gaining 
popularity for reasons such as fewer side effects, low cost and high accessibility and 
acceptability due to long history of use (Thomas, 2002; Vermani and Garg, 2002). There is, 
therefore, a need for data related to the efficacy of these medicinal plants. 
Leonotis leonurus and Artemisia afra are two of the most commonly used medicinal plants in 
South Africa traditionally advocated for use in asthma (Suliman, 2011). In the Eastern Cape 
Province of South Africa infusions of leaves of A. afra are used in the treatment of asthma 
(Thring and Weitz 2006). The leaves are also heated and the vapours inhaled to alleviate 
symptoms of asthma (Roberts 1990). Some tribes also commonly smoke the leaves to help 
relieve an acute attack (Roberts 1990).  On the other hand, the leaf infusion of L. leonurus has 
also been used for asthma and headaches (Van Wyk and Gericke, 2000). The infusion is 
taken on a regular basis to prevent attacks from occurring (Taylor et al., 2001). But it is not 
known whether or not this herb is helpful when administered during an actual asthma attack. 
Despite the vast traditional use of these two plants, very little is however known about the 
constituents/compounds responsible for, or the mechanism(s) involved in, producing the 
claimed anti-asthmatic effect.    
 
There are various physiological mechanisms by which current anti-asthmatic drugs produce 
their anti-asthmatic effect. The most effective and widely used agents generally produce anti-
inflammatory and smooth muscle relaxant effects, while some are mast cells stabilizers (Rang 
et al., 2003). The smooth muscle relaxant effect is particularly useful in acute attacks of 
asthma (Rang et al., 2003). The way the medicinal plants are used traditionally, strongly 
suggest that, if effective, they might be so because of a high potential of producing a smooth 
muscle relaxation. Now the crucial question will be which constituents in the plants are 
responsible for such smooth muscle relaxant effect. 
L. leonurus and A. afra contain a variety of constituents of which flavonoids are probably the 
most likely constituents known to be implicated in smooth muscle relaxation. A. afra contains 
flavonoids such as luteolin, kaempferol, apigenin, hesperetin, chrysoeriol, acacetin, 
genkwanin and quercetin (Muganga, 2004) with luteolin and quercetin present in higher 
levels than the others (Mulubwe, N.2007). Harris (2002) found that aqueous extracts of A. 
afra demonstrated a significant amount of smooth muscle relaxant effect, and also noted that 
flavonoid-rich fractions showed a greater bronchodilator effect. Similar to A. afra, L. 
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leonurus also contains a variety of flavonoids of which luteolin and hesperetin are the most 
abundant (Mulubwe, 2007). 
Several mechanisms have been investigated for the way in which flavonoids may be able to 
produce smooth muscle relaxation. They have been documented to block calcium ion 
channels, activate cGMP/PKG pathway, inhibit the release of histamine, xanthine oxidase, 
protein kinase C and phosphodiesterase (Yu and Kuo, 1995; Hayashi et al., 1988; Ferriola, 
1989; Kuppusamy and Das, 1992). Another mechanism may involve potassium channels, 
specifically KATP and BKca channels. For instance, Liu et al., (2008) demonstrated that 
isoliquiritigenin relaxes tracheal smooth muscle by stimulation of the cGMP/ PKG signalling 
cascade, resulting in the opening of the above mentioned potassium channels thus leading to 
smooth muscle relaxation. 
 Given the above arguments, the overall aim of this study was to determine whether A. afra 
and L. leonurus produced their anti-asthmatic effects in and by similar means. The specific 
objectives were therefore to compare the respiratory smooth muscle relaxant effects of 
freeze-dried aqueous extracts of A. afra and L. leonurus on tracheal smooth muscle 
contracted with mediators of asthma (i.e. histamine, carbachol and potassium chloride). It 
was hypothesized that the flavonoid levels and profile of A. afra would be greater than and 
different to the flavonoid levels and profile of L. leonurus, A. afra would have a more potent 
respiratory muscle relaxant effect than L. leonurus and that A. afra and L. leonurus will 
inhibit K
+
 -induced (i.e. KATP channel mediated) contractions in a superior manner than 
carbachol and histamine induced contractions. 
 
 
 
 
. 
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Chapter 2 
Literature review 
2.1 Introduction 
In this chapter a brief description of the selected plant species Artemisia afra, and Leonotis 
leonurus is given as well as the definition of asthma, current treatment and challenges of 
asthma therapy. In addition this chapter also discusses the chemistry, classification, biological 
activity and the analytical techniques suitable for the determination of flavonoids. It includes 
a brief description of the flavonoid luteolin with focus on its biological activities, 
pharmacokinetics and possible mechanisms of action as well as the rational for the use of 
isolated guinea pig trachea method for the investigation of A. afra and L. leonurus respiratory 
smooth muscle relaxant effects. 
 
2.2         Asthma 
2.2.1      Definition of asthma 
Asthma is defined based on its pathological, clinical and physiological characteristics with 
emphasis placed on chronic inflammation and hyper-responsiveness (Harkness et al., 2015; 
Murdoch and Lloyd, 2010). According to Global Initiative for Asthma (GINA), asthma is a 
chronic inflammatory condition of the airway which leads to hyper-secretion of the mucus 
glands, bronchoconstriction, and increased hyper-responsiveness of the airways, with 
involvement of many cells in particular mast cells, eosinophils and T lymphocytes. This 
chronic inflammation leads to recurrent episodes of breathlessness, reversible airflow 
obstruction, wheezing, chest tightness and coughing, particularly at night or in the early 
morning (GINA, 2015).  
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2.2.2      Aetiology of asthma 
Asthma pathogenesis develops as a consequence of complex interactions of genetic 
susceptibility and environmental influences i.e. timing and dose of allergen and co-exposure 
to infection. This ends in an inappropriate inflammatory response from a wide variety of 
inflammatory cells and mediators (Bateman et al., 2008; Murdoch and Lloyd, 2010). 
Asthmatic attack consists of two phases, the immediate and the late (delayed) phase.  The 
immediate phase of allergic asthma mainly results in bronchial spasms, mucous hyper-
secretion and mucosal oedema. During this phase, re-exposure to an antigen leads to antigen-
antibody interaction with  antigen presenting cells (APC),  dendritic cells, macrophages and 
mast cells on airway epithelial cells leading to release and synthesis of various mediators 
such as histamine, leukotrines (C4 and D4), prostaglandins D2  and tryptase  (Maddox and 
Schwartz, 2002; Robinson, 2010). The late phase occurs 2-8 hours after allergen inhalation 
and lasts up to 24 hours. It is associated with cellular infiltration (predominantly eosinophils 
and lymphocytes) and the progressive interaction of these cells with local cells (e.g., mast 
cells, macrophages, epithelial cells, endothelial cells) creates a cascade of events that 
contributes to the chronic inflammation and clinical manifestations associated with asthma 
(Holgate, 2011; Khan et al., 2008; Maddox and Schwartz, 2002). Mediators produced by this 
interaction are cytokines characteristically produced by T helper lymphocytes type 2 (Th2), 
particularly interleukins 4, 5, 9 and 13, eosinophils and the chemokine IL-8. In turn, these 
mediators attract other inflammatory cells, thereby contributing to further inflammation, 
sustained bronchoconstriction and mucus hyper-secretion (Maddox and Schwartz, 2002; 
Pelaia et al., 2015). Asthma due to antigen challenge is very common, but in some instances 
bronchoconstriction can be caused by non-antigenic stimuli such as exercise, distilled water, 
cold water and sulphur dioxide. This is called non-specific bronchial hyper reactivity to 
distinguish it from bronchial responsiveness to specific antigens (Maddox and Schwartz, 
2002; Rolph et al., 2006; Szczeklik and Stevenson, 2003). 
 
2.3         Treatment of asthma 
The main aim of asthma therapy is to control current asthma impairment and reduce future 
exacerbations. Anti-asthmatic drugs are grouped into two categories, anti-inflammatories 
(inhibits and prevents inflammatory process) and bronchodilators (reverse 
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bronchoconstriction) (Barnes, 2006). Within the current treatment guidelines, seven classes 
of drugs have been adopted, these include β2-adrenoceptor agonists (sympathomimetics), 
corticosteroids, selective muscarinic antagonists (anti-cholinergics), cromones (cromoglycate 
and necrodomil), xanthines (including theophylline - a precursor to the search for other 
phosphodiesterase (PDE) inhibitors, particularly of PDE4), cysteinyl leukotriene antagonists 
and the anti-IgE monoclonal antibody (Bateman et al., 2008). Drugs in common use are 
adrenoceptor agonists (used as relievers or bronchodilators) and inhaled corticosteroids (used 
as controllers or anti-inflammatory agents)  (Barnes, 2006; GINA,2015). 
 
2.3.1      Bronchodilators 
Drugs falling under this category include β2 - adrenoceptor agonists (sympathomimetic),   
xanthines, muscarinic receptor antagonists and cysteinyl-leukotriene receptor antagonists. 
2.3.1.1   Β2-adrenoceptor agonists 
The β2-adrenoceptor agonists are the most used bronchodilators for the treatment of asthma. 
They cause airway smooth muscle relaxation by acting on β2-adrenoceptors thereby 
stimulating adenylyl cyclase and increasing the formation of cAMP. They also inhibit tumor 
necrosis factor (TNF-α) and release of mediators from mast cells. Moreover, they increase 
mucus clearance by cilia action (Rang and Dale, 2015). There are different routes of 
administration for adrenoceptor agonists (i.e. oral, parenteral and inhalation) but delivery by 
inhalation is the preferred route due to it having the least systemic toxicity and the greatest 
local effect on airway smooth muscle. Β2-adrenoceptor agonists cause tachycardia and 
skeletal muscle tremor as toxic effects (Barnes, 2006; Pera and Penn, 2014; Rang and Dale, 
2015). 
The β2-adrenoceptor agonists can be divided into short acting and long acting β2 adrenoceptor 
agonists (SABAs and LABAs, respectively). SABAs are given by inhalation and used on an 
„as needed‟ basis to control symptoms.  Their effect occurs within 30 minutes and lasts for 
duration of 4-6 hours. Some degree of tolerance can occur if used for more than 2-3 weeks, 
but it can be reversed by parenteral steroids.  Similar to SABAs, Long acting agents are also 
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given by inhalation, but due to their high lipid solubility which allows them to dissolve in 
smooth muscle cell membrane in high concentrations, the duration of action is 12 hours. 
These drugs interact with corticosteroids to improve asthma control. Unlike SABAs, long 
acting agonists are not used as needed, but are given regularly, twice daily as adjunctive 
therapy in patients whose asthma is inadequately controlled by glucocorticoids (Barnes, 
2006; Bateman et al., 2008; Rang and Dale, 2015). 
2.3.1.2   Muscarinic receptor antagonists 
The cholinergic system is regarded to play a significant role in asthma. The binding of 
acetylcholine on muscarinic receptors in the airways induces a conformational change on the 
receptors which activates a cascade of events that leads to stimulation of airway smooth 
muscle and mucus glands, with subsequent bronchoconstriction and mucus secretion 
(Bateman et al., 2008). Muscarinic antagonists efficiently block the contraction and increased 
mucus secretion caused by vagal activity. They do not discriminate between muscarinic 
receptor subtypes, and it is likely that their blockade of M2-autoreceptors on the cholinergic 
nerves increases acetylcholine release and decreases the efficiency of their antagonism at the 
M3- receptors on the smooth muscle (Bateman et al., 2008; Rang and Dale, 2015). 
2.3.1.3   Methylxanthines 
 Methylxanthines are an exceptional class of drugs for treatment of asthma. They demonstrate 
efficacy in reducing the three principal features of asthma (reversible airflow obstruction, 
airway hyper-responsiveness, and airway inflammation). Bronchodilatory effects of 
methylxanthines are identified at doses at which toxic side effects are sometimes observed 
(Page and Barnes, 2004). At lower concentrations, methylxanthines are weak bronchodilators 
but retain their capacity as immune-modulators, anti-inflammatory, and broncho-protective 
drugs (Barnes, 2010). Several mechanisms of action have been suggested for the detected 
bronchodilatory and immunomodulatory effects of methylxanthines in the asthmatic airway. 
Phosphodiesterase (PDE) inhibition and adenosine receptor antagonism are the most 
established. Effects on mucociliary transport, inhibition of immune cell activation and 
proliferation and reduction in pro-inflammatory gene expression via the induction of histone 
deacetylase (HDAC) activity have also been reported (Rang and Dale, 2015; Tilley, 2011). 
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2.3.1.4   Cysteinyl-leukotriene receptor antagonists 
Cysteinyl-leukotriene receptor antagonists (LTRAs) are a fairly new form of asthma 
treatment that exerts bronchodilation and anti-inflammatory effects by blocking cysLT1 
receptors (Korenblat, 2000). Cysteinyl-leukotrienes (cysLTs) are lipid mediators synthesized 
from arachidonic acid by various cells, mostly eosinophils, mast cells, basophils and 
macrophages (Mastalerz and Kumik, 2010; O‟Byrne et al., 2009). They trigger contractile 
and inflammatory processes through the specific interaction with cysLT1 receptors on target 
cell surfaces. They are also responsible for mucous hyper-secretion, micro-vascular leakage, 
eosinophil chemotaxis and airway remodelling. They are involved in both immediate and late 
asthmatic responses induced by allergen exposure (Niimi, 2013). This class of antagonist 
drugs that blocks the binding of leukotrienes to cysLT1 receptors, has been given the generic 
suffix –lukast, and drugs based on these are known as leukotriene receptor antagonists. Three 
of these (i.e. montelukast, pranlukast and zafirlukast), together with 1 leukotriene synthesis 
inhibitor (zileuton), have been approved for use in the treatment of asthma (Korenblat, 2000; 
O‟Byrne et al., 2009). LTRAs are utilized as second- to third-line controller medication of 
persistent asthma and are highly safe and can be taken orally.  
  
2.3.2      Anti-inflammatory 
There are two different types of anti-inflammatories used in the treatment of asthma. 
Glucocorticoids which are used mainly in chronic conditions and sodium cromoglycate 
which are thought to affect their action by reducing bronchial hyper-reactivity. 
2.3.2.1   Glucocorticoids 
Glucocorticoids have become the predominant form of therapy for mild, moderate and severe 
persistent asthma due to their widespread anti-inflammatory properties. They mimic the 
action of the endogenous hormones (e.g. cortisol) that are involved in the regulation of the 
inflammatory response in the airways (Barnes, 2000; Rang and Dale, 2015). 
Glucocorticoids bind to the glucocorticoid receptor (GR) on target cells, and then the 
corticosteroid-receptor complex is rapidly transported to the cell nucleus where it alters the 
transcription of proteins associated with inflammation. Glucocorticoids also block production 
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or release of cytokines (in particular the Th2 that recruit and activate eosinophils), decrease 
the expression of adhesion molecules and influence the presence of cells that mediate 
inflammation. In terms of response, after the corticosteroid molecule enters the cell, hours or 
even days may elapse before significant quantities of new proteins are produced. This 
explains the delay in detecting the beneficial action of systemic corticosteroids (Barnes, 
2010; Bateman et al., 2008). Glucocorticoids are not effective in the treatment of the 
immediate response to the eliciting agent and do not reverse airway smooth muscle directly. 
However, they do reduce bronchial reactivity, frequency of asthma exacerbations, asthma 
symptoms, improve health-related quality of life, improve lung function, and decrease 
airways hyper-responsiveness (AHR)  (Barnes, 2010; Bateman et al., 2008; Rang and Dale, 
2015). In the management of chronic asthma, in which there is predominant inflammatory 
component, their efficacy is unequivocal.  
2.3.2.2   Sodium cromoglycate and nedocromil 
They are not bronchodilators, they do not have any effect on smooth muscle nor do they 
inhibit any of the known smooth muscle stimulants. If given prophylactically they can reduce 
both the immediate and the late phase asthmatic responses and reduce bronchial hyper-
reactivity  (Bateman et al., 2008). They are effective in antigen, exercise, and irritant induced 
asthma. Though not all asthmatic subjects respond and it is not possible to predict which 
patients will benefit. Children are more likely to respond than adults. Therefore these agents 
have become the anti-inflammatory drugs of first choice in children  (Barnes, 2006). Pre-
treatment with one of the agents before exposure to an eliciting stimulus may be very 
effective in young patients. Cromolyn and nedocromil differ structurally but are thought to 
share a common mechanism of action, an alteration in the function of delayed chloride 
channels in the cell membrane inhibiting cellular activation. Nedocromil‟s action on the 
airway nerves is thought to be responsible for inhibition of cough, on mast cells inhibition of 
early response to antigen challenge and on eosinophils for inhibition of the inflammatory 
response to inhalation to allergens, the inhibitory effect on mast cell seem to be specific to 
cell type.  
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2.4         Challenges of asthma therapy 
Current management of asthma is aimed at controlling disease symptoms and for the majority 
of asthmatics inhaled corticosteroids (ICS) with or without long-acting β2-agonists in 
combination are effective. However, even when taken regularly, ICS do not appear to modify 
the course of the disease significantly, and they are not curative. Asthma symptoms and 
inflammation rapidly recur when the treatment is discontinued. All currently available ICS 
are absorbed from the lungs and thus have the potential for systemic side effects. This has led 
to a concerted effort to find safer ICS, with reduced oral bioavailability and reduced 
absorption from the lungs or inactivation in the circulation. Concern has also been expressed 
about the long-term safety of LABA, although when administered in combination with ICS, 
this does not seem to be a problem (Barnes, 2012). But this approach requires lifetime 
therapy, and a subset of patients remains symptomatic despite optimal treatment. 
Furthermore, over 80 % of patients have poor adherence with regular inhaled therapy. A 
major unmet need in asthma is thus the development of more effective treatment, especially 
for patients with severe asthma who are relatively corticosteroid-resistant. The other unmet 
need in asthma is to develop effective oral therapy for patients with mild and moderate 
disease (Quirce et al., 2012). 
. 
 
2.5         The need for new therapies 
A major problem facing new drug development is that existing therapies for asthma, 
particularly combination inhalers, are highly effective, relatively inexpensive and safe, and 
there is a strong scientific rationale for this approach to asthma therapy (Page and Barnes, 
2004). This poses an enormous challenge in discovering drugs that improve on existing 
therapy. Another problem is that small animal models of asthma are poorly predictive of 
efficacy in asthma. Most drugs that are effective in animal models have failed in clinical 
trials, and drugs that might be effective would not be identified by these models. However, 
there are still concerns about the current treatment (Barnes, 2012). The types of new drugs 
needed for asthma include new classes that are effective in severe poorly controlled asthma, 
an oral treatment that is as effective as inhaled corticosteroids but without any side effects, 
and drugs that modify the course or even cure the disease. The approaches that have usually 
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been taken are to improve existing treatments, such as ICS and LABA, or to find drugs 
against novel targets identified through better understanding of the disease process, such as 
cytokine blockers. An oral therapy might have an advantage in that it would treat not only 
asthma but also rhinitis and atopic dermatitis, which are commonly associated, although oral 
therapies have a much greater risk of side effects (Weatherall et al., 2010). 
 
Many new treatments are specific, targeting a single mediator or receptor, and are unlikely to 
have a major clinical effect, although they might be effective in specific asthma phenotypes. 
Drugs with more widespread effects, such as kinase inhibitors, might be more effective, but 
have a greater risk of side effects (Barnes, 2010). New treatments targeting the underlying 
allergic/immune process would treat concomitant allergic diseases. Improved immunotherapy 
approaches have the prospect of disease modification, although prospects for a cure seem 
remote until the molecular and genetic causes of asthma are better understood. It has proved 
difficult to discover novel classes of therapy for asthma, despite intense effort and 
investment. Asthma is a very complex disease so it is unlikely that targeting a single receptor 
or mediator will be greatly effective (Barnes, 2010). The chronic nature of asthma and lack of 
preventive and curative therapy is leading researchers and asthma patients to seek alternative 
medicine treatment. 
 
 
2.6         Herbal medicine 
The World Health Organization (WHO) estimates that herbal medicines provide primary 
healthcare for approximately 3.5 to 4 billion people worldwide. Today, approximately 80 % 
of antimicrobial, cardiovascular, immunosuppressive, and anticancer drugs are of plant 
origin, their sales exceeded US$ 65 billion in 2003 (Gordaliza, 2009). It is widely accepted 
that more than 80 % of drug substances are either directly derived from natural products or 
developed from a natural compound (Dias et al., 2012). During the period 1981 to 2006, 47.1 
% of a total of 155 clinically approved anticancer drugs were derived from nature in North 
America, Europe, and Japan market (Newman and Cragg, 2007). In China, at least 130–140 
new drugs, either single chemical entities extracted from herbal medicines or synthetically 
modified compounds, are currently in clinical use (Pan et al., 2013). Some examples are 
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anisodamine (Poupko et al., 2007) indirubin (Suzuki et al., 2005), huperzine (Desilets et al., 
2009), and bicyclol (Pan et al., 2013). 
 
The historical importance of herbal medicine in the treatment of asthma is indisputable. Four 
of the five classes of drugs currently used to treat asthma namely, β2-agonists, anti- 
cholinergics, methylxanthines and cromones have origins in herbal treatments going back at 
least 5000 years (Bielory and Lupoli, 1999). The development of modern medicine still 
draws on clinical experiences from traditional medicines and therapies. In general, herbal 
medicines with a long history and theory of use in clinical settings should be more promising 
candidates for drug discovery (Pan et al., 2013). 
 
Based on their historical pattern of use and claimed efficacy, we suspect that A. afra and L. 
leonurus have good potential to possess anti-asthmatic activity. These two plants have an 
apparent widespread traditional use for bronchial conditions, a vast pattern of distribution and 
are easily obtainable by most people. These studies are necessary prerequisites for 
benefit/risk balance assessment of traditional practices and for formulation of standardized 
anti-asthmatic herbal drugs (WHO, 2002). 
 
 
2.7         Study of Artemisia afra and Leonotis leonurus 
2.7.1      Artemisia afra 
Artemisia afra is one of the oldest, best known and most widely used of all the indigenous 
medicines in Southern Africa (Thring and Weitz, 2006). The different or common local 
names describing this plant may be attributed to the extensive use by different ethnic groups 
(Watt and Breyer-Brandwijk, 1962). In the Xhosa it is known as “Umhlonyane”, in Zulu 
“Mhlonyane”, in Sotho “Lanyana”, Tswana “Lengana”, in English “African wormwood” and 
in Afrikaans “Wilde als”. 
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2.7.1.1   Botanical description 
A. afra is a highly aromatic plant. It is an erect multi-stemmed perennial shrub which grows 
up to two metres in height (Van Wyk et al., 1997). The feathery leaves are of soft texture, 
dark green on the adaxial surface and a lighter green on the abaxial surface, reaching a length 
of 8 cm and a width of 4 cm. A. afra blossoms from January to June, producing yellow, 
butter-coloured flowers with abundant bracts. In winter the branches die but rapidly 
regenerate from the base (Hilliard, 1977; Van Wyk et al., 1997).  
2.7.1.2   Taxonomy 
A. afra is classified into the Kingdom: Plantae, Division: Mannoliphyta, Class: 
Magnoliopsida, Sub-class: Asteridae, Order: Asterales, Family: Asteraceae, Genus: Artemisia 
and Species: Artemisia afra (Jackson, 1990). 
2.7.1.3   Distribution 
A. afra is widely distributed in Southern Africa, (i.e. South Africa, Namibia, and Zimbabwe). 
In South Africa, it grows in the northern provinces of Gauteng and Limpopo along the eastern 
parts of South Africa, including Swaziland and Lesotho, to the Western Cape in the south. It 
Figure 2.1: Artemisia afra in its natural habitat at Montague gardens, 
South Africa 
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is also abundantly found in KwaZulu-Natal province from the coast to the Drakensberg (Van 
Wyk et al., 1997; Hilliard, 1977) at altitudes of 20 to 2440 m on damp slopes, along 
streamside‟s and forest margins. 
 
Figure 2.2: Geographical distribution of A. afra in South Africa (Adapted from SATMERG 
Pharmacopoeia, Monographs Project, 1999). 
 
2.7.1.4   Medicinal uses  
 A. afra is traditionally widely used for numerous ailments including colds, coughs, malaria, 
convulsions, headache, inflammation, stomach disorders, whooping cough, colic, heartburn, 
diabetes mellitus, bronchitis and asthma among others (Roberts, 1990; Thring and Weitz, 
2006; Van Wyk et al., 2000; Watt and Breyer-Brandwijk, 1962). 
 Many different preparations of this plant are employed to treat the various symptoms and 
ailments. Syrup prepared from A. afra is used for bronchial troubles, while infusions or 
decoctions can be applied as a lotion to bathe haemorrhoids and for earache. An infusion of 
leaves or roots of this species is also used for the treatment of diabetes and respiratory 
problems in the Eastern Cape Province of South Africa. Respiratory infections are normally 
treated through inhaling the vapour from boiling leaves and this vapour is also used to treat 
menstrual chill. Fresh tips are inserted into the nose for colds and headaches and into hollow 
teeth to treat toothache (Erasto et al., 2005; Mahop and Mayet, 2007).  
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2.7.2         Leonotis leonurus 
L. leonurus is known under different vernacular names such as wild dagga; wilde dagga; 
lebake; umfincafincane and umhlahlampetu in English, Afrikaans, Zulu, Sotho, Xhosa and 
Shona, respectively. 
 
Figure 2.3: L. leonurus in its natural habitat at Montague gardens, South Africa. 
 
2.7.2.1       Botanical description 
This attractive plant species is a shrub of two to five meters in height with thick, woody base 
and pale brown branches. All parts of the plant have a strong smell. The leaves are opposite 
each other on the stems that are long and narrow, toothed in the upper half and distinctly 
hairy. L. leonurus has bright orange, tubular flowers that are borne in characteristic rounded 
groups and are neatly arranged along the branch ends. The hairy flowers resemble lion‟s ears, 
hence the name „leonurus‟ which means lion‟s ears (Van Wyk et al., 2000). 
2.7.2.2       Taxonomy 
Leonotis leonurus is classified into Kingdom: Plantae, Order: Lamiales, Family: Lamiaceae 
Genus: Leonotis, Species: L. leonurus (Van Wyk et al., 2000). 
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2.7.2.3       Distribution 
L. leonurus has a wide natural distribution over large parts of South Africa and has become a 
popular garden plant (Van Wyk et al., 2000). 
2.7.2.4      Medicinal uses  
Numerous traditional uses have been reported for L. leonurus. It is used to treat asthma, 
colds, influenza, bronchitis, high blood pressure, headache and viral hepatitis. In addition, it 
is used to treat boils, eczema, skin diseases, itching, muscular cramps, snakebite, other bites 
and stings (Van Wyk and Gericke, 2000). L. leonurus leaves and stems are mainly used, but 
sometimes also the roots. Decoctions of L. leonurus are used externally for skin problems and 
internally, either by mouth or as an enema, to treat coughs, colds, fever, headaches and high 
blood pressure. In addition, leaf infusions have been used for asthma and viral hepatitis 
(Thring et al., 2006; Van Wyk et al., 2000). Because it is only mildly narcotic, there are 
reports of the plant being smoked as a substitute for dagga. It has, however, been smoked for 
the relief of epilepsy. In Europe, this traditional phytomedicine is used for the symptomatic 
treatment of coughs in acute bronchial disease (Van Wyk and Gericke, 2000). 
 
2.8         Common features of Artemisia afra and Leonotis leonurus 
A. afra and L. leonurus are amongst the most popular used medicinal plants in South Africa. 
They are traditionally used to treat many conditions such as asthma (Thring and Weitz, 
2006). However, proper scientific studies to validate these claimed uses are lacking. The few 
studies conducted on A. afra have reported it to possess smooth muscle relaxant properties 
(Harris, 2002).  
For these plants to be developed into new drugs that meet the criteria of modern medicine, 
they have to be thoroughly investigated. For effective research on these plants to be 
conducted, various systems such as animals, tissue culture techniques and cell lines need to 
be used. 
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2.9       Evaluation of asthma medication using animal models 
Asthma is a uniquely human disease and, with the exception of perhaps cats (eosinophilic 
bronchitis) (Reinero, 2011; Venema and Patterson, 2010) and horses (heaves) (Herszberg et 
al., 2006), no animals, including those commonly used to study asthma (mice, rats, guinea 
pigs and rabbits) naturally exhibits an asthma like syndrome that is similar to the disease in 
humans. The utility of animal models of asthma to understand human disease and to develop 
therapeutics is the topic of considerable debate (Holmes et al., 2011; Persson et al., 1997). 
Several species and study designs have been used to try and model human asthma, suggesting 
that there is no generally accepted model of the human disease. Species and strain 
differences, variations in sensitisation and challenge schedules, and the method by which 
drugs are delivered to the lungs (e.g. intranasal or intra-tracheal instillation of solutions, 
nebulised compounds, or dry powders) are all parameters that can influence the outcome of a 
study. The extent to which these factors affect study outcomes, and the potential impact that 
they have on the relevance of these models to humans, is difficult to determine. Little 
information exists in the publically available literature, suggesting that further research to 
better characterise these parameters is required. Nonetheless, for obvious ethical reasons the 
types of experiments required to dissect accurately the mechanisms that are involved at 
cellular and molecular levels are not possible in humans. 
 
Animal models of asthma have been in use for more than 100 years  (Karol, 1994). While, as 
with any model of disease, the link between the processes observed in the animal and humans 
needs to be carefully considered, they are an ideal vehicle for identifying and testing 
mechanisms linked to the development of the asthmatic phenotype. The species chosen and 
method used dependents highly on the specific aspect of the disease that is of interest. Some 
species or strains are better for modelling particular characteristics of asthma than others. Out 
of all the species, mice, rats as well as guinea pigs are the most commonly employed models 
for studying the effect of drugs on respiratory smooth muscle (Brewer et al., 1999; Zhang, 
2008). 
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2.9.1    Mouse model of asthma      
Mouse models of allergic airway disease offer numerous advantages when compared to the 
use of other animals. Immunoglobulin E (IgE) is the primary allergic antibody in mice, 
making this species appropriate for investigation of the role of humoral immune factors in 
allergic airway disease. Further, mouse models offer the opportunity to explore detailed 
mechanisms of allergic reactions because of the availability of numerous immunological 
reagents such as antibodies against cytokines, growth factors, and cell surface markers 
(Shapiro, 2008). Moreover, the emerging technologies involving gene manipulation in 
animals are well-advanced in mice. The ease of breeding and short gestational period is an 
additional advantage. Accordingly, major advances in the understanding of the disease 
concept, asthma as Th2 dominant disease emerged from studies in mice. A disadvantage with 
mouse models is the considerable physiologic differences that exist between mice & humans 
(Canning and Chou, 2008; Shapiro, 2008).  
2.9.2    Rat models of asthma  
Rats are also popular as models of allergic airways disease. Like mice, they are relatively 
cheap, which allows large scale studies on multiple outcomes to be conducted. Historically, 
as experimental models, rats were more popular than mice, but have been overtaken in recent 
years due to the rapid expansion of genetic technologies associated with mice (Holmes et al., 
2011). Rats represent a significant advantage over mice due to their larger size. This makes it 
easier to measure the classic characteristics of allergic airways disease such as airway and 
systemic markers of inflammation due to an increase in the volume of serum and 
bronchoalveolar lavage (BAL) that can be obtained (Holmes et al., 2011; Karol, 1994). This 
larger size and their increased stability under anaesthesia may also be seen as an advantage in 
terms of measuring physiological outcomes such as airway hyper- responsiveness and acute 
responses to allergen inhalation. Rats are often used as a standard model for testing new drug 
therapies; in particular, the efficacy and toxicity of new drugs are often tested in rats before 
proceeding with clinical trials. However, it should be highlighted that rats have lower 
sensitivity to bronchoconstrictors (i.e. more agonist is necessary to produce a narrowing of 
the airways) than guinea pigs (Hylkema et al., 2002; Karol, 1994; Martin and Tamaoka, 
2006). 
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2.9.3    Guinea pig model of asthma  
The guinea pig model was the first described model of asthma and contributed greatly to the 
development of receptor agonist therapies. Many fundamental processes, mediators and 
regulators of airway disease pathogenesis were discovered or demonstrated first in guinea 
pigs, including the Schultz–Dale (immediate type hypersensitivity) reaction, the actions of 
histamine, the cysteinyl-leukotrienes and their two receptors, beta adrenoceptor subtypes, 
thromboxane, alveolar macrophage derived neutrophil chemotactic factor(s) and the roles of 
cyclic adenosine monophosphate (cAMP) and inositol triphosphate in signal transduction 
(Jones et al., 1988; Suckow et al., 2012). Receptor pharmacology in guinea pigs more closely 
matches that of human receptor pharmacology than most other commonly used species 
(Canning and Chou, 2008; Muccitelli et al., 1987; Ressmeyer et al., 2006). Several 
breakthroughs in measuring lung mechanics were first made in studies using this species, 
while models of the late phase response following an allergen challenge have been perfected 
in guinea pigs  (Amdur and Mead, 1958; Meurs et al., 2006). However, the emergence of 
transgenic mouse studies has and will continue to result in the diminished use of guinea pigs 
for modelling airways disease. This is unfortunate, as for many endpoints guinea pigs are 
superior to mice for studies of processes related to asthma (Canning and Chou, 2008; Meurs 
et al., 2006; Persson et al., 1997). 
 
2.10       Techniques to measure the effect of plants in asthma 
For evaluations of pharmacological effect of plants with anti-asthmatic effect, three types of 
methods can be used, i.e. in-silico, in vivo and in vitro methods. 
2.10.1    In-silico models 
Computer simulations used to generate virtual ligand-receptor interactions, cells, respiratory 
tracts, and patients are the newest trend in modelling allergic asthma. In-silico screening to 
identify novel drugs might become a useful tool and can be divided into virtual drug 
discovery, virtual organs and virtual patients. 
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2.10.1.1 Virtual drug discovery  
An example of virtual drug discovery in allergic asthma is a computational screening of 
ligand-receptor interactions based on 3-D structure of the X-ray analysis of a particular 
binding site (Patel, 2014). This creates a 3-D „pharmacophore‟ model, which generates a 
pattern of spatial and chemical constraints of the ligand. This approach was used to produce 
non-peptidic antagonists of Very Late Antigen-4 (VLA-4), an adhesion molecule involved in 
cell-cell interactions (Patel et al, 2014). 
2.10.1.2 Virtual organs  
A variety of computer simulations of lungs have led to the so called, „lung physiome‟ or 
„virtual lung‟. These simulations provide physiological measurements of healthy and 
asthmatic lungs, and can be used for testing drug efficacy. One example is the simulation of a 
3-D human respiratory tract using magnetic resonance imaging (MRI) and a single-photon 
emission computed tomography (SPECT) images from lungs and thorax. The virtual 
respiratory tract enables one to evaluate lumen diameter based on bronchoconstriction, 
inflammation and mucosal thickness and has been used to predict the efficiency of aerosol 
drug delivery in healthy versus asthmatic subjects (Patel et al , 2014). 
 2.10.1.3 Virtual patients  
The virtual allergic asthmatic patient promises to be the next generation of in-silico model. 
One example is the virtual rat lung model developed to determine the effects of 
environmental pollution on lung function. A second example is a computer-based 
mathematical model of airway structure and function, inflammation, and immune responses 
to create virtual asthmatic patients. A major aim of the virtual patient model is to reduce the 
cost of getting new drugs to market (Patel et al, 2014). 
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2.10.2    In vitro methods 
There are several in vitro methods that are used that are based on the measurement of: 
2.10.2.1   Reactivity of the isolated perfused trachea  
The method is used to evaluate the effect of the epithelium on trachea muscle reactivity. 
Contractile agonists are either added on the serosal or mucosal surface in stepwise increasing 
cumulative concentrations. The trachea from the animal is removed, attached to a stainless 
steel perfusion holder and placed in an organ chamber filled with Krebs solution. The 
solution is maintained at 37 °C and aerated with 95 % O2 plus 5 % CO2. The solution is also 
pumped at a constant rate through the mucosal lumen. The inlet and outlet catheters are 
connected to the positive and negative sides, respectively, of a force transducer. Responses 
are quantified as ΔP in centimetres of H2O. Responses of the musculature are obtained by 
measuring changes in inlet-outlet ΔP between side holes of indwelling catheters.  Geometric 
EC50 values are determined from least square analysis of a logit model and are presented 
along with 95 % confidence intervals (Fedan et al., 2001; Vogel, 2002). 
 
2.10.2.2   Bronchial perfusion of isolated lung  
This method has been used to evaluate pharmacological reactions of sympathomimetic drugs 
on bronchiolar muscle. The trachea and lungs of the animal are removed and the trachea is 
attached to a cannula of a perfusion apparatus which pumps the solution at a constant rate in a 
monometric tube connected with the perfused organ. Only one lung is perfused, the other is 
tied off. The lower part of the lower lobe is cut off and the rest of the lung surface is 
scratched deeply assuring maximum pre-medication flow. Liquid is poured down the trachea 
through the bronchi and escapes the lung through the alveoli. Resistance to flow 
(bronchoconstriction) results in an increase in the height of the column of fluid in the 
manometer. The intensity of the bronchodilator effect is measured by the fall of the column in 
the manometer. (Vogel, 2002) 
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2.10.2.3   Vascular and airway responses in the isolated lung  
The isolated perfused rat lung method allows the simultaneous registration of pulmonary, 
vascular and airway responses to various drugs. Pulmonary arterial perfusion pressure, 
airway pressure, and reservoir blood level are continuously monitored, electronically 
averaged and recorded. The lungs are ventilated by a certain amount of negative pressure and 
a tidal volume. Artificial thorax chamber pressure is measured with a differential pressure 
transducer, and air flow velocity with a pneumotachograph tube connected to a differential 
pressure transducer.  The arterial pressure is continuously monitored by means of a pressure 
transducer which is connected with the cannula ending in the pulmonary artery. All data is 
transmitted and analysed on a computer (Fedan et al., 2001; Vogel, 2002). 
 
2.10.2.4   Spasmolytic activity in isolated trachea  
The isolated trachea model is used to evaluate the compounds ability to induce 
bronchodilation or prevent bronchoconstriction. Tracheas from the animals are dissected and 
prepared free of adhering fat and connective tissue. These prepared trachea tissues are 
mounted in organ baths filled with Krebs solution. The solution is maintained at 37 °C and 
aerated with 95 % O2 plus 5 % CO2. To achieve steady spontaneous tone level, an initial 
tension of 1-2 g is applied for at least 1 hour with washing at 15-minute intervals. 
Bronchospasm is induced on the respiratory smooth muscle. If the compound induces 
relaxation, bronchospasm of the respiratory smooth muscle will reduce upon administration 
of the compound. When an increase in concentration produces no further increment in 
response, the tissue is washed to re-establish the baseline tension. Cumulative concentration 
curves are constructed and percentage inhibition of the spasmogens induced contractions is 
calculated. From dose-response curves EC50 values are calculated (Blume and Davies, 2013; 
Englert et al., 1992; Vogel, 2002). 
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2.10.3    In vivo methods 
2.10.3.1 Broncho-spasmolytic activity in anesthetized guinea pigs (Konzett-Rössler 
method)  
The method is based on registration of air volume changes of a living animal in a closed 
system consisting of the respiration pump of the trachea and the bronchi as well as of a 
reservoir permitting measurement of volume or pressure of excess air. Administration of 
spasmogens like acetylcholine, histamine, and bradykinin results in contraction of bronchial 
smooth muscle, bronchospasm decreases the volume of inspired air and increases the volume 
of excess air. Thus, the degree of bronchospasm can be quantified by recording the volume of 
excess air. This method permits the evaluation of a drug‟s bronchospasmolytic effect by 
measuring the volume of air, which is not taken up by the lungs after bronchospasm. The 
results from the bronchial constriction caused by spasmogens are expressed as percentage 
inhibition of induced bronchospasm over the control agonistic responses. From this, the ED50 
value is calculated (Blume and Davies, 2013; Bonfield, 2012). 
 
2.10.3.2.   Bronchial hyper reactivity method 
In this method guinea pigs are introduced to bronchospasm inducing agents such as histamine 
through aerosols produced by an ultra-sound nebulizer so as to mimic anaphylactic 
convulsions resembling bronchial asthma in patients. The animal is placed in an inhalation 
cage to which the test drug or substance is introduced using an ultra-sound nebulizer. 
Alternatively the animal is treated orally or subcutaneously with the test drug or substance. 
The animal is then passed to another inhalation cage where it is exposed to bronchospasm 
inducing agents and time until appearance of anaphylactic convulsions is measured. 
Symptoms first observed include increased breathing frequency, forced inspiration, and 
finally anaphylactic convulsions. The introduction of antagonistic drugs can then delay the 
occurrence of these symptoms. Evaluation is determined from the percentage increase of pre-
convulsion time versus controls and ED50 values can be calculated, i.e. 50 %  increase of pre-
convulsion time (Blume and Davies, 2013).   
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2.10.3.3.   Pneumotachography in anesthetized guinea pigs method 
The use of a pneumotachograph is based on the principle of the Fleisch – tube and of 
additional pressure transducers. It allows simultaneous measurements of pulmonary 
mechanics, respiratory parameters and circulatory parameters in anesthetized guinea pigs (De 
la Motta, 1991).  A cannula is inserted to the trachea then connected with pieces of tubing to 
a Fleisch tube (pneumotachograph). The Fleisch tube is connected with sensitive differential 
pressure transducers, both of which are connected to a pre-amplifier. The signals for airflow 
are monitored at the output of the pre-amplifier with a digital 2-channel oscilloscope. The 
signals are presented at the output of the instrument as analogue electrical signals on a 
computer. For each individual experiment, data of the last 5 minutes before the first substance 
application are averaged and used as controls. The response values after substance 
application are then expressed as percentages of the controls. For an analysis of the results the 
response values are averaged over certain time intervals (Glaab et al., 2007; Vogel and 
Vogel, 2013). 
 
2.10.3.4.   Airway micro-vascular leakage method 
In this method Evans Blue dye and radio labelled albumin are used to determine plasma 
exudation in guinea-pig airways. This method can be used to study the antagonism against 
bradykinin- and platelet-activating factor-induced airway micro-vascular leakage and vagal 
stimulation-induced airway responses (Rogers et al., 1989; Vogel, 2002). The animal is 
anesthetized then a tracheal cannula inserted in the lumen of the cervical trachea, a catheter 
into the left carotid artery to monitor blood pressure and heart rate and another catheter into 
the external jugular vein for administration of drugs. The test compound (antagonist) is given 
intravenously. Ten minutes later Evans Blue dye is injected intravenously for 1 minute. 
Bronchoconstriction and micro-vascular leakage is induced by inhalation or injection of 
bradykinin. The thoracic cavity is then opened 6 minutes later, and a cannula inserted in the 
aorta through a ventriculotomy in order to remove the intravascular dye from the systemic 
circulation. The lungs are removed, blotted dry and Evans Blue dye extracted. Between the 
treated and control groups, Evans Blue dye concentration as well as lung resistance are 
compared by statistical means (unpaired Student‟s t-test or Mann- Whitney U test). 
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2.10.3.5. The effects of respiratory depressant drugs in conscious rats method 
This is a non-invasive method for distinguishing central from peripheral nervous system 
effects of respiratory depressant drugs in conscious rats using gas and sodium cyanide 
exposures and carotid body denervation. Group means and standard errors of the (Fedan et 
al., 2001) means (SEM) are presented for all quantitative data. Mean values of treated groups 
are considered to be statistically different from the control group if the calculated P value is < 
0.05 (Vogel, 2002). 
 
In silico, in vitro and in vivo methods all have their various advantages and disadvantages. In 
this study an in vitro spasmolytic activity in isolated trachea method was used. 
 
2.11      Trachea preparations  
Although there are marked differences between species, with regard to innervating, receptors 
and neuromodulatory mechanisms, dissected guinea pig trachea tissue immersed or 
superfused by isolated tissue bath techniques provides important ways to study the effects of 
drugs on the neural pathways, or on the smooth muscle directly. The guinea pig trachea is 
generally accepted as a relevant and sensitive model of human large and central airways, 
which enable the screening of new compounds with potential therapeutic effect. There are 
two main techniques in which the trachea can be prepared for testing of smooth muscle 
activities, immersion techniques and superfusion techniques. 
2.11.1     Immersion techniques 
The isolated trachea tissue is immersed in an isolated tissue bath warmed to 37 °C from a 
constant temperature circulator. The tissue is suspended in Krebs-Henseleit (KH) solution 
and fixed to the bottom of the bath chamber on one side, and on the other side to an isometric 
force transducer for measurement of change in force as the tissues contract. A mixture of 95 
% O2 and 5 % CO2 is continuously bubbled from the bottom of the bath chamber for 
oxygenation, mixing and pH maintenance (Uhlig and Taylor, 2012). Some examples of 
immersion techniques include tracheal chain, spirally cut trachea, the zig-zag trachea strip 
and trachea tube preparation.  
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2.11.1.1    Trachea chain 
Trachea chain preparation was introduced by Castillo de Beer and initially used to study the 
relaxant effects of relaxant drugs, especially those acting on the β2-adrenoceptors. The guinea 
pig trachea is dissected and then divided into four to six trachea rings, which are tied together 
by a cotton thread. These chains are then immersed in the isolated tissue bath as described 
above. Contractile agents (i.e. histamine, acetylcholine, carbochol, KCL) or relaxant drugs 
(i.e. β2-adrenoceptor agonists, methylxanthines, papaverine, sodium nitoprusside), are 
introduced in the tissue bath  in 0.5 log unit increments, and from the  isomeric tension 
changes, cumulative concentration  response curves are generated. Contractile or relaxant 
responses are expressed as percentage values of the maximum response caused by a reference 
compound. Disadvantages of the trachea chain preparation are the tedious process of tying 
the trachea chains together and the small maximum responses recorded, compared to that 
observed with other trachea preparations. Advantages are that the system is sensitive to 
changes in response (Castillo and De Beer, 1947; Uhlig and Taylor, 2012).   
2.11.1.2    Spirally cut trachea  
This is a changed and enhanced technique, which disposes of the time intensive procedure of 
entwining the tracheal rings and which has the extra advantage of creating more prominent 
force. The trachea is sliced diagonally to deliver a few fragments, each containing up to five 
trachea rings. By means of stainless steel wire introduced into the tracheal lumen, spirally 
structured strips can be formed briefly by cutting the connective tissue to separate the rings in 
a way that they are still held together by a little portion of the connective ligament between 
every single ring. After mounting the twisting strips in tissue baths containing KH solution 
under resting tension of (e.g. 1-2 g) and development of unconstrained tone, isometric 
compressions to cumulative added spasmogens, can reproducibly be measured for 6 hours. 
Advantages of this method are the faster rate of preparation and the significant improvement 
of force. Anderson and Lee showed the resistance of bronchodilator medications in vitro by 
utilizing the spirally cut trachea (Uhlig et al., 1998).   
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2.11.1.3    Zig-zag trachea strip 
A comparative preparation to that of a spirally cut trachea is the instantly prepared zig-zag 
strip portrayed by Emmerson and Mackay. The trachea is cut longitudinally, by slicing 
through the cartilage rings opposite the trachealis muscle, and after that, traverse slits are cut 
into the connective tissue at equally spaced interval, first on one side of the strip, then on the 
other. The spiralling tissue is cut into required number of lengths (2-4) of equivalent size 
needed for the test. Strings are tired to every end of the tissue, which are set up in the isolated 
tissue bath(s) as previously portrayed under a resting tension of 1-2 g (Allegra et al., 1993; 
Uhlig and Taylor, 2012).   
 
Further advantages other than the pace of preparation, is that the zig-zag trachea strip 
preparation has been utilized in different applications, bringing about the determination that 
predominantly cAMP and less cyclic guanosine monophosphate (cGMP), play a critical part 
in the regulation in guinea pig tracheal smooth muscle tone. β2 -adrenoceptor agonists cause 
relaxation by stimulating cAMP, and agents that inhibit cyclic nucleotide phosphodiesterase 
(PDE) have been predicted to apply a greater portion of their relaxant impact by increasing 
intracellular cAMP level (Uhlig and Taylor, 2012). 
The electrically stimulated version of the zig-zag strip has often been used to investigate the 
nonadrenergic, noncholinergic (NANC) innervation and neurotransmission of the guinea-pig 
trachea. In other cases the electric field stimulated trachea has frequently been used to study 
indirectly the modulation of neurotransmitter release from airway nerves, by measuring post-
junctional response. It can in this manner be seen that a zigzag strip is an important 
mechanism with a wide application bringing about the determination of imperative 
mechanisms happening in smooth muscle (Uhlig and Taylor, 2012).    
 
2.11.1.4    Trachea tube preparations 
These include: 
(i) Un-stimulated perfused trachea tube:  dissected trachea preparation suspended in 
organ bath, but lack lumen-epithelium interface. 
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(ii) Transmural stimulation: another version of the intact trachea tube that is not 
perfused, but suspended, and subjected to electric field stimulation. 
(iii) Sympathetic and vagus nerve stimulation:  the trachea is removed with 
sympathetic and vagus nerves attached and cannulated at both ends, and mounted 
horizontally in an organ bath (Uhlig et al., 1998) 
. 
2.11.2       Superfusion techniques 
This is another method, used to a lesser extent, but sometimes more appropriate, e.g. to 
perform a bioassay of perfusates and evaluation of potency of labile substances or those of 
extremely low quality. An apparent beneficial effect of this method is the ability to rapidly 
remove potentially toxic metabolites, preventing them from accumulating in the tissue, and 
thereby reducing the washing time. Techniques employed under this method include, 
electrically stimulated zigzag trachea strip and epithelium-denuded trachea (Uhlig et al., 
1998).   
 
 
2.12       Contraction and relaxation of smooth muscle. 
As described by Webb (2003), various agonists (neurotransmitters, hormones, etc.) bind to 
specific receptors to activate contraction in smooth muscle. Subsequent to this binding, the 
prototypical response of the cell is to increase phospholipase C activity via coupling through 
a G protein. Phospholipase C produces two potent second messengers from the membrane 
lipid phosphatidylinositol 4, 5-bisphosphate: diacylglycerol (DG) and inositol 1,4,5-
trisphosphate (IP3). IP3 binds to specific receptors on the sarcoplasmic reticulum, causing 
release of activator calcium (Ca
2+
). DG, along with Ca
2+
, activates Protein kinase C (PKC), 
which phosphorylates specific target proteins. In most smooth muscles, PKC has contraction-
promoting effects such as phosphorylation of Ca
2+ 
channels or other proteins that regulate 
cross-bridge cycling. Activator Ca
2+
 binds to calmodulin, leading to activation of myosin 
light chain kinase (MLC kinase). This kinase phosphorylates the light chain of myosin, and, 
in conjunction with actin, cross-bridge cycling occurs, initiating shortening of the smooth 
muscle cell. However, the elevation in Ca
2+ 
concentration within the cell is transient, and the 
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contractile response is maintained by a Ca
2+ 
sensitizing mechanism brought about by the 
inhibition of myosin phosphatase activity by Rho kinase. This Ca
2+ 
sensitizing mechanism is 
initiated at the same time that phospholipase C is activated, and it involves the activation of 
the small GTP-binding protein RhoA. The precise nature of the activation of RhoA by the G 
protein-coupled receptor is not entirely clear but involves a guanine nucleotide exchange 
factor (RhoGEF) and migration of RhoA to the plasma membrane. Upon activation, RhoA 
increases Rho kinase activity, leading to inhibition of myosin phosphatase. This promotes the 
contractile state, since the light chain of myosin cannot be dephosphorylated (Webb, 2003). 
 
Smooth muscle relaxation occurs either as a result of removal of the contractile stimulus or 
by the direct action of a substance that stimulates inhibition of the contractile mechanism. 
Regardless, the process of relaxation requires a decreased intracellular Ca
2+ 
concentration and 
increased MLC phosphatase activity. The sarcoplasmic reticulum and the plasma membrane 
contain Ca,Mg-ATPases that remove Ca
2+ 
 from the cytosol. Na
+
/Ca
2+
 exchangers are also 
located on the plasma membrane and aid in decreasing intracellular Ca
2+
. During relaxation, 
receptor- and voltage-operated Ca
2+ 
channels in the plasma membrane close resulting in a 
reduced Ca
2+
 entry into the cell (Webb, 2003). In the case of KATP channels induced 
relaxation in the airway smooth muscle, several endogenous agonists (e.g. intracellular 
nucleotides and calcitonin-gene related peptide) activate KATP channels resulting in 
hyperpolarization and relaxation (Sutovska et al., 2007). 
 
The compounds in plant products such as in A. afra and L. leonurus could probably affect the 
smooth muscle in asthma by blocking anti-muscarinic receptors, anti-histaminergic receptors 
and activating KATP channels. 
 
2.13        Flavonoids 
Flavonoids are a diverse group of low molecular weight secondary plant phytochemicals. 
They are important compounds in the human diet and are widely distributed in the plant 
kingdom as intrinsic components of fruits, vegetables and beverages. They play a vital role in 
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plant growth and development, and in plant defence against microorganisms. Over 4,000 
flavonoid compounds have been identified (Havsteen, 2002). 
 
 
Figure 2.4: General structural formula of flavonoids. 
 
2.13.1    Chemistry and classification 
Flavonoids are recognized by the presence of a C6-C3-C6 phenyl-benzopyran skeleton 
comprising of two aromatic rings (A and C) connected by a three carbon unit which could 
possibly structure a third ring (B) (Grotewold, 2006). The position of the phenyl ring in 
connection to the benzopyran moiety permits division of these compounds into flavonoids (2-
phenyl-benzopyrans), isoflavonoids (3-phenyl-benzopyrans) and neoflavonoids (4-phenyl-
benzopyrans), they can further be partitioned into subclasses based on  substitution patterns 
of ring C, the oxidation state of the heterocyclic ring and the position of ring B (Mukinda et 
al., 2010). These basic variations may explain the observed contrasts in bioactivity identified 
with these compounds. The most well-known sub-classes are the flavones, flavonols, 
flavanones, catechins, isoflavones and anthocyanidins, which represent around 80 % of 
flavonoids (Aherne et al., 2007). Flavones and flavonols have been identified in almost all 
plants. The ones found most frequently being those with B-ring hydroxylation in the C-3 and 
C-4 positions (Havsteen, 2002). Flavonoid molecules not attached to sugar moieties are 
referred to as the aglycones, whereas flavonoid molecules with sugar moieties are called 
flavonoid glycosides (Markham, 1982). 
 
The chemical nature of the flavonoids depends on structural class, degree of hydroxylation, 
other substitutions, conjugations, and degree of polymerization (Harborne and Williams, 
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2000). In plants, the flavonoids are relatively resistant to heat, oxygen, dryness and moderate 
degrees of acidity.  
Flavonoids containing a pyran ring i.e. a hydroxyl group in position C3 of the C ring are 
classified as 3-hydroxyflavonoids (i.e. the flavonols, anthocyanidins and catechins) and those 
lacking a hydroxyl group in position C3 as 3-desoxyflavonoids i.e. the flavanones (e.g. 
hesperetin, naringenin) and flavones (e.g. luteolin, apigenin) (Markham, 1982).  
 
 
Figure 2.5: Structures of the main classes of flavonoids. 
 
2.13.2    Biological activities 
Flavonoids have a wide range of biological or pharmacological activities. These include anti-
oxidation, anti-inflammation, anti-platelet, anti-tumour, anti-angiogenic, antiviral anti-
thrombotic action, anti-allergic effects and smooth muscle relaxation. Furthermore, they 
inhibit enzymes such as cyclooxygenase, lypoxygenase, prostaglandin synthase, xanthine 
oxidase, protein kinase c and phosphodiesterase (Ko et al., 2004). Within the last decade, 
flavonoids have emerged as potential alternatives for treating diabetes, hyperlipidemia and 
oxidative stress, involving multiple signalling pathways (Heim et al., 2002). Luteolin (the 
main flavonoid of interest in this study) has been reported to relax tracheal  smooth muscle 
(de Rojas et al., 1995; Ko et al., 2004). 
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2.14.      Luteolin 
Luteolin is one of the most common flavonoids present in edible plants and in plants used in 
traditional medicine to treat a wide variety of ailments. It is most often found in leaves, barks, 
clover blossom, rag weed and pollen.  
Luteolin is present as an aglycone (molecule without any sugars bound to it) in some plants 
such as perilla seeds and as glycosides (molecule with one or several sugars bound to it) in 
celery, green pepper, perilla leave, chamomile tea, etc (Shimoi et al., 1998). Most glycosides 
of luteolin are O-glycosides, i.e., the sugar moieties are bound to the aglycone through one or 
more of the four free hydroxyl (OH) groups (Figure 2.3). These glycosides usually have sugar 
moieties at position 5, 7, 3‟ and 4‟, as luteolin is 5, 7, 3‟, 4‟- tetrahydroxyflavone (Lopez-
Lazaro, 2009; Shimoi et al., 2001).  
 
 
Figure 2.6: The structure of Luteolin and Luteolin-7-0-glucoside. 
 
2.14.1    Biological activities of luteolin  
Luteolin may be a significant, accessible developing pharmacological agent because of its 
numerous advantageous properties. It has been shown that luteolin has anti-inflammatory and 
antispasmodic action (Lopez-Lazaro, 2009), cancer prevention activity (Areias et al., 2001), 
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anti-allergic and immune-modulatory properties to suppress hyperactive immune system 
(Shimoi et al., 1998). Moreover, luteolin has been shown to be a developing anti-cancer agent 
that totally represses the catalytic action of eukaryotic DNA topoisomerase I (Chowdhury et 
al., 2002; Gálvez et al., 2003). It  additionally helps in the prevention of the neo-vascular 
infection of the eye by repressing corneal angiogenesis in vivo (Joussen et al., 2000). More 
importantly, because of its anti-allergic, anti-inflammatory and smooth muscle relaxing 
properties, luteolin has potential in the prevention and treatment of numerous respiratory 
conditions including asthma and chronic bronchitis (Havsteen, 2002; De Rojas et al., 1995; 
Sadzuka et al., 1997). The smooth muscle relaxant effect of luteolin is possibly mediated via 
inhibition of cyclic adenosine monophosphate (cAMP) - and cyclic guanosine 
monophosphate (cGMP)-phosphodiesterases (Ko et al., 2005). Phosphodiesterase inhibition 
has also been implicated in trachea smooth muscle relaxation of the flavonoid luteolin (Ko et 
al., 2005).   
 
 
2.15.      Analytical techniques suitable for the determination of flavonoids 
Several techniques can be used to separate, identify and quantitate flavonoids. They include 
gas chromatography (GC), high performance liquid chromatography (HPLC) or capillary 
electrophoresis (CE). Among these (HPLC) appears to be the most popular and applicable 
technique for the analysis of flavonoids in plant extracts, because it is a sensitive, rapid, and 
economical technique, which can be used in the separation, identification and quantification 
of flavonoids in plant extracts  (Kalili and de Villiers, 2011; Khoddami et al., 2013; Stalikas, 
2007). 
 
HPLC is essentially a manifestation of column chromatography that uses a high-pressure 
pump to create rapid flow of eluent, and therefore radically enhancing analysis time. Various 
components  influence HPLC analysis of flavonoids, including sample purification, mobile 
phase, column types and detectors (Picó, 2012; Stalikas, 2007). All in all, flavonoids are 
essayed with a HPLC instrument utilizing a reversed phase C18 column (RP-C18), photo 
diode array detector (PDA) and polar acidified organic solvents (Merken and Beecher, 2000; 
Naczk and Shahidi, 2004; Zarena and Sankar, 2012). Generally, acetonitrile and methanol, or 
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their aqueous forms, are the prevailing mobile phases used in HPLC evaluation of phenolics 
(Khoddami et al., 2013; Stalikas, 2007; Zarena and Sankar, 2012). 
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Chapter 3 
Plan of work 
 
3.1         Introduction  
In this chapter the objectives set, hypotheses to be tested and the study approach followed to 
compare the flavonoid profile and respiratory smooth muscle relaxant effects of Artemisia 
afra versus Leonotis leonurus are presented. 
3.2         Objectives 
The overall aim of this study was to determine whether Artemisia afra and Leonotis leonurus 
produce their anti-asthmatic effects in and by similar means and the specific objectives were 
to: 
 Determine and compare the flavonoid profiles and levels in Artemisia afra and 
Leonotis leonurus (as traditionally used), 
 Compare the respiratory smooth muscle relaxant effects of freeze-dried aqueous 
extracts of  Artemisia afra and Leonotis leonurus  and 
 Investigate whether K+ - channel activation (i.e. KATP channel) was one possible 
mechanism of action that can explain the effect obtained in traditional use of these 2 
plants. 
To realize these objectives it was decided to determine the effects that the plants and select 
flavonoids may have on contraction induced by agonists (carbachol, histamine and KCl) 
known to be mediators of bronchoconstriction. And, to determine the flavonoid profiles of 
hydrolysed and un-hydrolysed aqueous plant extracts a HPLC assay was used. 
 
3.3         Hypothesis 
We hypothesized that: (i) A. afra has greater respiratory muscle relaxant effect than L. 
leonurus, (ii) A. afra and L. leonurus will inhibit K
+
 -induced (i.e. KATP channel mediated) 
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contractions in a superior way than carbachol and histamine induced contractions, and (iii) 
that the freeze-dried aqueous extract of A. afra has a different flavonoid profile and greater 
flavonoid levels than L. leonurus extract.  
3.4         Study approach 
To realize the above objectives, freeze-dried aqueous extracts were prepared, an appropriate 
method for determining smooth muscle relaxant effect selected and used, and a sensitive 
assay procedure employed to determine the profiles and levels of free and total flavonoid 
forms in the plant materials. Motivation for this approach is as follows: 
3.4.1      Form of A. afra and L. leonurus used 
Traditionally aqueous extracts of A. afra and L. leonurus are used and have been claimed to 
have smooth muscle relaxant activity (Harris, 2002). In this study freeze dried aqueous 
extracts of A. afra and L. leonurus were to be used.  These aqueous extracts are relatively 
easy to prepare, convenient to store and stable (and thus consistent in chemical composition) 
if properly stored, and would mimic the dry form of the traditionally used tea dosage form. 
3.4.2   Method for determination of smooth muscle relaxant effect of A. afra and L. 
leonurus  
For this study the isolated guinea pig tracheal smooth muscle model was used. It is a well-
established, standard and commonly used tool in the preclinical research phase of anti-asthma 
drug discovery, especially because guinea pigs are particularly sensitive to the general 
triggers that initiate asthma in humans (Canning and Chou, 2008). Moreover the model is 
particularly useful for evaluation of the mechanism of action of such drugs and has 
previously been used in the testing of a herbal product, viz. A. afra (Harris, 2002). The zig-
zag tracheal strip method was chosen due to its rapid and easy mode of preparation, and the 
tissue can be used for up to 10 hours. From the knowledge of the known mediators of 
bronchoconstriction in allergic inflammatory respiratory conditions, it was decided to focus 
on histamine, carbachol and potassium channel mediated constriction in this study since these 
mediators are commonly focused on in preclinical testing of anti-asthmatic drugs. The 
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isolated zig-zag cut guinea pig trachea muscle model was thus used to compare the degrees of 
smooth muscle relaxation of A. afra versus L. leonurus and to determine whether the 
relaxation caused by the two plants were more K
+
 channel mediated. The focus on the K
+
 
channel (i.e. KATP channel mediated) mechanism was motivated by KATP channel openers that 
have been shown to have airway smooth muscle relaxation activity, and more importantly, 
because this mechanism has never been studied in these two plants. 
 
3.4.3.     The focus on flavonoid profile & luteolin levels in A. afra and L. leonurus  
 
Flavonoids have been identified in both A. afra and L. leonurus crude extracts (Harris, 2002; 
Muganga, 2004). Some studies have shown flavonoids (particularly luteolin and quercetin) to 
induce smooth muscle relaxation (Ko et al., 2004; Polya, 2003). Consequently, it was decided 
to focus on flavonoids and, primarily, luteolin, as the marker flavonoid compound for this 
study. Both A. afra and L. leonurus are expected to contain luteolin, but little has been 
scientifically reported on the effects of luteolin-containing A. afra and L. leonurus on 
respiratory smooth muscle relaxation. At the same time, luteolin might also serve as an 
effective marker compound for the flavonoid group as a whole. To determine the flavonoid 
profile and luteolin levels a HPLC assay method was employed because it is a sensitive, rapid 
and economical technique. It was of particular interest to determine if A. afra had greater 
luteolin levels than L. leonurus and whether such a difference would match with the 
difference in relaxant activity.  
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Chapter 4 
Determination of flavonoid profiles and luteolin levels in A. afra 
and L. leonurus 
 
4.1  Introduction 
In this chapter the materials, reagents, equipment, methods and procedures used to prepare 
the freeze dried aqueous extract (FDAE) of A. afra and L. leonurus for analyses are 
discussed. The development and validation of the HPLC assay used for quantitation of 
luteolin in A. afra and L. leonurus is described, the determination of flavonoid profiles and 
levels presented, and the results obtained discussed.  
 
4.2.  Chemicals and materials  
4.2.1  Chemicals 
Acetonitrile, methanol (HPLC grade), ethyl acetate, acetic acid, hydrochloric acid and 
acetone were all solvents purchased from Merck (Darmstadt, Germany). Luteolin standard 
was purchased from Sigma (St. Louis, USA). Distilled water used was prepared in the 
pharmacology laboratory in the School of Pharmacy and purified using the Analyst HP water 
purifier (Oxon, England). 
4.2.2  Equipment 
Analytical  balance (Mettler®, model PE 6000), a scientific balance (Ohaus®, model GA 
110), a freeze- dryer (Virtis ®, Freeze mobile model 125L), -85°C freezer (Lozone CFC 
Freezer, Model U855360, New Brunswick Scientific, USA), a water bath (Labcon®, model 
CDH 110 Maraisburg, SA), filtration system (SUPELCO) connected to vacuum pump (Medi-
Pump Model 1132-2, Thomas Industries, Inc., USA), filter paper (Whatman No. 41 & 
Whatman No.1, Whatman, England), oven (Model Memmet 854 Schwabach, West Germany), 
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a centrifuge (Multex MSE®, England), desiccators, a vortex mixer (Vortex-2, G-560E, 
Scientific Industries, Inc. Bohemia, N.Y. 11716 USA), test sieve shaker (Endecott sieve 
shaker, E.F.L. 1MK11, Endecotts (test sieve) LTD, London, England), micropipettes, Agilent 
1200 Series HPLC system equipped with a quaternary pump (model G1311A), photodiode 
array detector (PDA) (model G1315B), in-line degasser (model G1322A), column oven 
(G1329A) and PC with ChemStation software (Chemetrics, South Africa),   reverse phase C-
18 column (Phenomenex, USA) with a 5 m particle size, and column length of 4.6 mm x 250 
mm. 
4.2.3 Plant materials 
A. afra and L. leonurus leaves were purchased from a local industrial herbal supplier, 
Grassroot Group (Pty) Limited (Groenvlei farm, South Africa), placed in plastic bags and 
stored in a cool place at room temperature away from sunlight until use.  
 
4.3         Methods and procedures  
4.3.1      Preparation of A. afra and L. leonurus extracts 
To mimic the form used in traditional medicine, A. afra and L. leonurus were dried and 
extracted as described in literature by herbal practitioners. In traditional use, a quarter cup 
quantity of medicinal plant leaves is allowed to stand in a cup of boiling water for 10 minutes 
(Roberts, 1990). However, in this study, the dried leaves were suspended in distilled water 
(100 g of dried leaves in 3.5 L of distilled water) and the mixture boiled for 30 minutes.  
After boiling, the decoction obtained was left to cool before it was filtered using Whatman 
no. 1 filter paper, the filtrate transferred to a round bottom flask and frozen at -85 °C in a 
freezer. The frozen extract was then dried under vacuum using the Virtis™ mobile freeze-
dryer. The resultant extract powder was analysed for its organoleptic features and weighed to 
determine the percentage yield. Thereafter, the freeze-dried aqueous extract (FDAE) powders 
were placed in stoppered amber glass bottles and stored at room temperature in desiccators 
until used. 
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4.3.2 HPLC method development and validation 
4.3.2.1   Method development 
The method described by Dube (2006), with some modifications, was used. Luteolin was 
selected as a marker for the comparison of the level of active compounds in A. afra and L. 
leonurus. Separation was effected on a Phenomenex Luna C-18 column with 5 µm particle 
size and a column length of 250 x 4.60 mm and the column was kept at 25 °C. The mobile 
phase consisted of 0.1% formic acid in distilled water (solvent A) and 0.1% formic acid in 
acetonitrile (solvent B). The elution gradient was: 0-22 min 15% B; 22-27 min 40% B; 27-28 
min 100% B and 28-33 min 15% B. The solvents were filtered and degassed by membrane 
filtration prior to use. The eluent was pumped at a flow rate of 0.8 ml/min, with injection 
volume of 20 µl. The luteolin peaks were detected at 350 nm.  
4.3.2.2   Preparation of calibration standards 
A stock solution of luteolin (1 mg/ml) was prepared by weighing out a certain amount of 
luteolin standard and dissolving it in methanol. Standard solutions were prepared on the day 
of use by diluting the stock solution with methanol to concentrations of 0.5, 1, 2, 4, 8 and 16 
µg/ml. 
4.3.2.3  Validation of the HLPC assay 
The validation of the method for suitability and effectiveness is the most important part in 
method development. Method development is only complete when acceptable analytical 
performance has been demonstrated (Bräter et al., 1994). The validation tests conducted 
included determination of calibration curve linearity, assay specificity, accuracy and 
precision and limits of detection and quantitation.  
4.3.2.3.1 Linearity (calibration curve)  
For each luteolin calibration sample mentioned in section 4.3.2.2, 20 µl was injected onto the 
column. The areas obtained in the chromatogram for the luteolin peaks were noted and 
plotted against their concentrations to obtain a calibration curve. The linearity of the curve 
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over the concentrations studied was determined by linear regression analysis using the least 
square regression method. 
4.3.2.3.2  Detection and quantitation limits (sensitivity) 
The limit of detection (LOD) and quantitation (LOQ) for the luteolin reference standard was 
determined by the signal-to-noise ratio method (Shah et al., 2010) using peak area as the 
analyte response. LOD was defined as the lowest concentration level resulting in a peak area 
of three times (3:1) the baseline while LOQ was defined as the lowest concentration level that 
provided a peak area with signal to noise ratio of higher than ten (10:1). Both limits were 
calculated from the relative standard deviation (RSD) and slope(s) of the calibration curves 
using equations LOD = 3.3 (RSD/S) and LOQ = 10 (RSD/S).  
4.3.2.3.3 Accuracy and precision 
The precision of the HPLC method was determined by calculating the repeatability (intra-
day) and intermediate precision (inter-day). For this, 3 replicates of samples  containing  high 
(16 ug/ml), intermediate (4 ug/ml) and low (0.5 ug/ml) concentrations of luteolin were 
assayed each day on 3 consecutive days and on each occasion the average, standard deviation 
and % relative standard deviation (RSD) calculated and compared to determine the intra-day  
and inter-day precision. The accuracy of the method was determined by the mean 
concentrations obtained from the replicates and the percentage difference.   
4.3.2.3.4    Specificity and stability  
To determine the specificity of the assay, a series of luteolin samples were subjected to a 
variety of conditions (listed below) and thereafter injected onto the HPLC system to assess 
the analytes in the presence of degradants/impurities which may arise. 
To determine the effect of acid hydrolysis, 100 µl of concentrated HCl was added to an 8 
µg/ml solution of luteolin. The samples were then heated at 60 
o
C for 1 hour, cooled and 
injected onto the HPLC column. To determine the effect of heat a solution of 8 µg/ml luteolin 
was heated at 60 
o
C for 3 hours in a water bath. The sample was then cooled and 20 µl 
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injected onto the HPLC column.  In each case the chromatograms were analysed for peak 
area, purity and presence of additional peaks. 
 
 4.3.3  Quantification of luteolin in the plant preparations 
A. afra and L. leonurus preparations were assayed in two ways, viz. as hydrolysed and un-
hydrolysed samples. From the latter the level of free flavonoids and the former the level of 
total flavonoid in the plant extracts were determined. 
4.3.3.1   Determination of free flavonoid levels  
For this, 10 mg FDAE A. afra and L. Leonurus were each weighed in labelled centrifuge 
tubes, 1 ml of distilled water added, the tubes shaken, 5 ml of ethyl acetate added the mixture 
vortexed for 1 minute and centrifuged for 10 minutes at 3000 rpm. Thereafter, the top layer of 
ethyl acetate was removed and transferred to a clean tube using a disposable plastic pipette 
and evaporated to dryness under a gentle stream of nitrogen. To the residue, 1 ml of mobile 
phase (acetonitrile: water 50:50) was added, the tube gently vortexed for 20 seconds and the 
solution drawn up into a 2 ml syringe (without needle). A 0.22 μm membrane syringe filter 
was then attached to the syringe and the solution filtered and transferred to a labelled HPLC 
vial. Twenty microliters of each sample was then injected onto the HPLC column for 
analysis.  
4.3.3.2        Determination of total flavonoid levels  
For this, 10 mg FDAE A. afra and L. leonurus were each weighed in labelled centrifuge 
tubes. One millilitre of distilled water was added and the mixture vortex-mixed for 20 
seconds. To hydrolyse the samples, 2 ml of 2 M hydrochloric acid was added to the plant 
solutions and the mixture heated at 80 °C for 40 minutes in a water bath. Thereafter the tubes 
were removed, allowed to cool for 10 minutes, 5 ml ethyl acetate added and the samples 
mixed with a vortex mixer for 1 minute and centrifuged for 10 minutes at 3000 rpm. The 
ethyl acetate top layer was then transferred to a clean tube using a disposable plastic pipette 
and evaporated to dryness under a gentle stream of nitrogen. To the residue 1 ml of mobile 
phase (acetonitrile : water 50:50) was added, the tube gently vortexed  for 20 seconds, the 
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solution then drawn into a 2 ml syringe (without needle),  filtered (using 0.22 μm membrane 
syringe filter) and transferred to a labelled HPLC vial. Twenty microliters of each sample 
was then injected onto the HPLC column for analysis. 
To identify luteolin in the plant samples, the retention time and UV-spectra of the possible 
luteolin peaks were identified and compared with the UV-spectrum and the retention time 
obtained in the chromatograms of the standard reference luteolin sample.  
 
4.4         Results and discussion  
4.4.1      Organoleptic properties of freeze-dried aqueous extracts (FDAE) 
The A. afra extract was a light brown, brittle and hygroscopic powder with a characteristic 
and aromatic odour. The extract of L. Leonurus produced was brown, brittle and hygroscopic 
and also had a characteristic odour. The samples of extract produced provided sufficient 
material for the entire study. The average yield for the freeze dried aqueous extract was 21.8 
% and 19.5 % for A. afra and L. leonurus, respectively. These yields were very close to those 
obtained by previous investigators, e.g.  19.9 % by Komperlla (2005) and 21.96 % by Dube 
(2006) for A. afra, and 18.42 % by Ma (2006) for L. leonurus.  
4.4.2.    Validation of HPLC assay 
Under the HPLC conditions used in this study, symmetrical chromatographic peaks of 
luteolin were obtained at 23.14 ± 0.255 minutes (figure 4.1). In this study, the absorbance of 
luteolin was read at 350 nm, which differed slightly from the 349 nm maximum wavelength 
for luteolin recommended by Markham (Markham, 1982; Muganga, 2005) and the 340 nm 
used by Waithaka for luteolin from A. afra (Waithaka, 2004). 
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Figure 4.1: HPLC chromatogram for the luteolin reference standard at 350 nm. Insert: 
UV/V spectrum for the reference compound with peak at 23.5 min. (n=3) 
4.4.2.1   Linearity and range 
The standard curve of peak area versus luteolin was found to be linear (r
2
= 0.9998) over the 
concentration ranges studied (0.5 to 16 µg/ml) (figure 4.2). Linearity in this range was 
sufficient to provide a highly accurate value for the luteolin content in the plant samples. The 
standard curve was described by the equation y = 131. 27x-22.759 (where Y= peak area ratio, 
X = luteolin concentration in µg/ml). Using the established calibration curve, the content of 
luteolin in the plant extracts was quantified. Linearity, linear regression equation and 
correlation coefficients of the concentration ranges for the reference compound are given in 
figure 4.2 and table 4.1. 
 
 
 
 
45 
 
  
Figure 4.2: Calibration curve of mean peak area against the concentration of 
replicate samples of luteolin at 350 nm. 
 
 
 
Table 4.1:  Concentration versus peak area of luteolin monitored at 350 nm 
Concentration 
(µg/mL) 
Mean peak area (mAU) (n = 3) %RSD 
0.5 54.0 10.1 
1 115.6 6.6 
2 233.4 7.5 
4 497.2 2.9 
8 1011.5 5.6 
16 2086.9 3.9 
 
4.4.2.2   Accuracy and precision 
Accuracy and precision values calculated during the intra- and inter-day assay runs are given 
in tables 4.2 and 4.3 
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Table 4.2: Intra-day variations of HPLC method for determination of luteolin   
 
 
 
 
 
 
Table 4.3: Inter-day variations of HPLC method for determination of luteolin  
 
Method precision had a relative standard deviation (RSD) below 10 % for repeatability and 7 
% for intermediate precision. In both cases, percent RSD values were found well within 10 
%, suggesting that the method provided highly reproducible results. The accuracy results 
were expressed as percent recoveries, and these fell within the range of 98.23 to 110.80, 
indicating good accuracy of the proposed HPLC method. 
 
4.4.2.3 Detection and quantitation limits.  
The minimum concentration levels at which the analytes could be detected (LOD) was 0.159 
µg/ml and quantified (LOQ) was 0.482 µg/ml (Table 4.4). 
 
 
 
Concentration 
(ug/ml) 
Mean peak area 
(mAU)       (n=3) 
Standard 
deviation 
%RSD Mean 
Concentration 
found 
0.5 54.333 3.459 6.366 0.597 
4 472.224  22.312 4.723 3.875 
16 2021.210  48.707 2.409 16.029 
Concentration 
(ug/ml) 
Mean peak 
area ( mAU)     
(n=9) 
Standard 
deviation 
% RSD Mean 
Concentration 
found (ug/ml) 
% recovery 
0.5 59.544 6.068 10.191 0.554 110.801 
4 508.911 44.235 8.692 3.929 98.230 
16 2117.744 110.207 5.204 16.015 100.090 
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Table 4.4: Assay validation parameters for luteolin quantification in A. afra and L. 
leonurus preparations 
 
 
 
 
 
 
 
 
4.4.2.4   Specificity and stability 
A series of samples were subjected to a variety of conditions and injected onto the HPLC 
system to assess the analytes in the presence of degradants which may emerge, Figures 4.3 
and 4.4 show chromatograms of luteolin samples after acid and heat treatment, respectively. 
The luteolin peak remained symmetrical in shape and the peak retention time was maintained. 
The luteolin peak areas were not significantly affected by acid (p = 0.0896) and heat (p = 
0.2428) treatment. The UV/Vis spectrum was unchanged and no evidence of extra peak(s) of 
degradation products was evident. The results obtained from the HPLC system software peak 
purity tool demonstrated that the peak of luteolin was pure and the purity factor was within 
the calculated threshold in all cases, thus confirming the absence of other substances in the 
same retention time, suggesting that, under these conditions, luteolin was stable. This HPLC 
assay was very specific for un-hydrolysed and hydrolysed A. afra as well as  un-hydrolysed 
L. leonurus (figures 4.5, 4.6 and 4.7, respectively), but it was not specific for hydrolysed L. 
leonurus samples as it did not completely manage to separate luteolin from some peaks close 
to or interfering with the luteolin peak (fig 4.8).  
 
Validation parameters Parameter value 
Retention time of luteolin (min) 23. 140 
Linearity-Regression of coefficient (R
2
) 0.9998 
Inter-assay precision (RSD in 3 days) (%) 8.029 
LOD ( µg/ml) 0.159 
LOQ (µg/ml) 0.482 
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Figure 4.3: HPLC chromatogram for the luteolin reference standard at 350 nm after the addition of acid 
(HCl) and heating at 60 
o
C for 1 hour. The inserted diagrams indicate the peak purity and 
UV spectrum. (n=3) 
 
 
Figure 4.4: HPLC chromatogram for the luteolin reference standard at 350 nm after subjection to 
heating at 60 
o
C for 3 hours. The inserted diagrams indicate the peak purity and UV 
spectrum. (n=3) 
  
4.4.3      Identification and level of luteolin in A. afra and L. leonurus preparations 
The above-mentioned validated HPLC assay was used to identify and quantitate the levels of 
luteolin in the un-hydrolysed and hydrolysed A. afra and L. leonurus plant preparations. The 
hydrolysed and un-hydrolysed samples of plant extracts were analysed and representative 
chromatograms obtained for each plant are given in figures 4.5 to 4.8. 
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Figure 4.5: HPLC chromatogram of un-hydrolyzed A. afra. The retention time of luteolin (L) is 23.1 
min. 
 
 
 
Figure 4.6: HPLC chromatogram of acid hydrolysed A. afra. The retention time of luteolin (L) is 23.0 
min. 
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Figure 4.7: HPLC chromatogram of un-hydrolyzed L. leonurus in which the retention time of luteolin (L) is 22.9 
min 
 
 
Figure 4.8: HPLC chromatogram of acid hydrolysed A. afra. The retention time of luteolin (L) is 22.9 min 
 
 
Table 4.5: Levels of luteolin in A. afra and L. leonurus plant preparations 
Plant samples Luteolin concentration (µg/mg of plant 
extract) Mean ± SD (n=3) 
Conjugated luteolin (%) 
Free luteolin Total luteolin 
A. afra  8.977 ± 0.73 16.394 ± 0.884 45 
L. leonurus 0.929 ± 0.066 3.093 ± 0.531 69 
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Collectively, the results confirmed the presence of quantifiable amounts of luteolin in A. afra 
and L. leonurus extracts. To the best of my knowledge, studies concentrating on the presence 
of luteolin in L. leonurus have not been done previously. Other researchers have, however, 
previously reported on the presence of luteolin in A. afra (Muganga, 2004; Waithaka, 2004).  
Chromatograms of the hydrolysed and un-hydrolysed A. afra and L. leonurus samples 
showed peaks of several other compounds, of which most had a UV/Vis spectrum similar to 
that of flavonoids. The luteolin peak (retention time 23.14 ± 0.255 min) was identified by 
spiking samples and by UV spectral analysis done using the diode array detector.  
The flavonoid profile of un-hydrolysed A. afra showed roughly 14 distinctive (above height 
of 6) peaks, and 10 of the peaks had UV/Vis spectrum similar to that of flavonoids. The un-
hydrolysed L. leonurus on the other hand displayed around 19 distinctive peaks with 13 peaks 
exhibiting UV/Vis spectrum similar to that of flavonoids. Extra peaks were evident from both 
plants after acid hydrolysis. In general, L. leonurus had a greater flavonoid profile than A. 
afra.  
The luteolin peak height in the un-hydrolysed A. afra was 51.7 mAU, but after hydrolysis it 
had increased to 143 mAU. Similar, but to a lesser extent the luteolin peak height of un-
hydrolysed L. leonurus was 5.4 mAU but after hydrolysis it was 7.8 mAU. A. afra contained 
8.977 ± 0.73 µg free luteolin/mg while L. leonurus contained only 0.929 ± 0.066 µg free 
luteolin/mg (Table 4.5). A. afra contained four to five times as much free luteolin than L. 
leonurus (p = 0.0026). On the other hand, A. afra contained 16.394 ± 0.884 µg total 
luteolin/mg FDAE whereas L. leonurus contained 3.093 ± 0.531 µg total luteolin/mg FDAE. 
After acid hydrolysis, luteolin levels in A. afra (p = 0.0004) and L. leonurus (p = 0.018) were 
significantly increased in comparison with the un-hydrolysed plant samples (Table 4.5). Acid 
hydrolysis presumably leads to increase in peak height of aglycones as a result of flavonoid 
glycoside hydrolysis to flavonoid aglycones (Baranowska and Magiera, 2011). About two 
thirds of the luteolin from both plants was in the glycoside form. L. leonurus had a 
substantially greater percentage of glycosides (79 %) than A. afra (45 %), meaning that 
although L. leonurus has a lower load of luteolin it has more of the conjugated form. 
Compared to L. leonurus, A. afra contained very little acid hydrolysable (i.e. conjugated) 
luteolin glycosides (Table 4.5). 
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  4.4.4.     Conclusion 
Overall, from the results acquired the following conclusions could be drawn. 
Moderate to good yields of 21.8 % and 19.5 % were obtained for FDAE A. afra and L. 
leonurus, respectively. The HPLC method used for quantitative analysis of luteolin proved to 
be suitable for fingerprinting of luteolin and was sufficiently accurate and reproducible for 
the quantitative analysis of luteolin in FDAE A. afra and L. leonurus. Finally, A. afra had 
significantly higher levels of total and free luteolin than L. leonurus, with relatively low 
values of total and free luteolin observed in L. leonurus. However, L. leonurus contained a 
greater percentage of its luteolin in the conjugated form than A. afra.  
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Chapter 5 
Respiratory smooth muscle relaxant effects of A. afra and L. 
leonurus 
 
5.1        Introduction 
One specific objective of this study was to compare the respiratory smooth muscle relaxant 
effects of freeze-dried aqueous extracts of A. afra and L. leonurus and to determine whether 
KATP – channel activation is one possible mechanism of action that can explain the effect 
obtained with the traditional use of these two plants. Other researchers have found Artemisia 
afra to possess smooth muscle relaxant effects, we thus hypothesized that: (i) Artemisia afra 
would have a greater respiratory muscle relaxant effect than Leonotis leonurus, and (ii) that 
A. afra and L. leonurus will inhibit K
+
 -induced (i.e. KATP channel mediated) contractions in a 
superior manner than carbachol and histamine induced contractions. In this chapter, the 
chemicals, materials and methods used to establish and compare the tracheal smooth muscle 
relaxant effects of the 2 plants and their possible mechanisms of action are reported, and the 
results obtained are presented and discussed. 
 
5.2     Chemicals, materials and equipment, 
5.2.1   Chemicals 
 Carbachol, histamine diphosphate salt, isoproterenol hydrochloride (isoprenaline), rutin and 
quercetin were all obtained from Sigma-Aldrich, S.A. (Pty) Ltd. Sodium pentobarbitone 6 % 
injection was purchased from Kryon Lab (Pty) Ltd (South Africa). All drugs and reagents 
were dissolved in distilled water, unless noted otherwise. Composition of Krebs-Henseleit 
solution (mM) was: NaCl 118, KCl 4.77, CaCl2 2.0, MgSO4 1.2, NaHCO3 25, KH2PO4 1.2, 
and glucose 11. All these chemicals were obtained from Merck Laboratory and were of 
analytical reagent (AR) grade. 
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5.2.1.1     Preparation of stock solutions 
Stock solutions of histamine (1 mM), carbachol (1 µM) and potassium chloride (100 mM) in 
the Krebs-Henseleit solution (KH) were freshly prepared 24 hours before use. The KH stock 
solution (minus glucose) was freshly prepared and refrigerated at 2
o
C
 
until use when glucose 
was added. The KH stock solution was discarded 10 days after preparation.  
5.2.2      Materials 
Surgical equipment was purchased from Lasec (Pty) Ltd, South Africa. The PowerLab
® 
data 
acquisition system controlled by the LabChart
® 
version 7 data analysis software was supplied 
by AD Instruments (Australia).  A. afra and L. leonurus extracts, as described in chapter 4, 
were used in this set of experiments. 
5.2.3      Equipment 
5.2.3.1   The organ bath system 
The system used is shown in figures 5.1 and 5.2 and consisted of a 15-ml  water jacketed 
glass organ bath (A) that was supplied with perfusion medium (KH) from a 2 L reservoir (B). 
On its way from the reservoir the perfusion fluid passed in tubing through a condenser (C) 
and the perfusion flow was controlled via two taps (D). Fluid was drained via another tap (E) 
and outlet tubing from the organ bath.  Perfusion medium in the bath was kept at 37 
o
C by 
circulating water through the jackets of the condenser and the organ bath with the aid of a 
thermo-stated water bath (F). The perfusion medium in the tissue bath was aerated with a 
mixture of 5 % CO2 and 95 % O2 from a cylinder and via a 5 ml syringe needle inserted in the 
top of the bath. To measure contractile responses, the tissue was held at a fixed position with 
the aid of cotton threads tied to stainless steel tissue holder (K) located at the bottom of the 
bath and to a force transducer (G). Contraction of the trachea created tension on the force 
transducer, and this was converted into a voltage signal at the pre-amplifier. Signals from the 
pre-amplifiers were channelled to an analog to digital converter (H)  connected to a desktop 
computer (J) running the Labchart
®
 7 software (I) that allowed continuous recording of 
tension throughout the experiment. Two of the above organ bath systems (figure 5.1) were 
 
 
 
 
55 
 
connected in series to allow the simultaneous execution of two replicates of the experiment 
(A). 
 
Figure 5.1: The isolated organ bath system used for the bronchodilator experiments in the laboratory. 
A = Two organ bath systems; B = 2 Litre reservoir; C = Condenser; D = Taps controlling 
perfusion flow; E = Taps draining perfusion fluid; F = Thermo-stated water bath; G = Force 
transducer; H = Powerlab
®
, I = Labchart
®
 7 software; J = Desktop computer. 
 
 
Figure 5.2: Part of the organ bath system showing a stainless steel hook (K) used in the 
bronchodilator experiments in the laboratory. 
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Figure 5.3: A close-up of an isolated organ bath showing a condenser and a force 
transducer to which a zigzag trachea tissue is fixed. A = organ bath systems; 
C = Condenser; D = Tap controlling perfusion flow; E = Tap draining 
perfusion fluid; G = Force transducer 
 
To quantify the contractile and relaxant responses of the tracheal muscle the force 
transducers, amplifiers and recorders were calibrated as follows. First, the reading on the 
Labchart
®
 7 was set to zero then low weights (0.5 to 5 g) were attached to the transducer and 
the tensions recorded. Finally, a plot of mass (force) versus recorder reading was established 
and this calibration was done before each series of experiments. 
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5.3         Methods 
5.3.1     Measurement of contractile force in isolated tracheal preparation 
5.3.1.1   Animals 
Male and female pathogen-free Dunkin Hartley guinea-pigs (350–460 g) were purchased 
from the Centre for Animal Studies (North West University). Before they were used they 
were housed at the School of Pharmacy (UWC) animal room under controlled conditions, 
with lighting regulated to produce day and night conditions (12-hour cycle). They were 
allowed free access to water and commercial chow. The experiments were approved and 
carried out in accordance with the ethical requirements of the University of The Western 
Cape Animal Research Ethics Committee (AREC). 
5.3.1.2   Tissue preparations   
For each experiment, one guinea pig was weighed and anaesthetized with sodium 
pentobarbital (50 mg/kg) intra-peritoneally. The throat and chest of the animal was cut open 
from under the chin to the thorax and the trachea exposed and quickly excised by cutting 
below the bronchial bifurcation and above the pharynx. The excised tissue was rinsed in 
chilled KH solution and transferred to a dissecting dish also containing chilled KH solution. 
During cleaning, the trachea was held at the pharynx or below the bifurcation so as to prevent 
applying the forceps directly on the trachea itself. Surgical scissors were used to trim off any 
adhering fat and connective tissue. The trachea was then cut open on the cartilage ring side 
with surgical scissors, flattened and pinned below the bifurcation and above the pharynx on 
the dissecting dish with disposable syringe needles. Thereafter the opened trachea was cut 
parallel to the cartilage rings to form zigzag strips of equal widths i.e. one cartilage ring per 
segment. Each cut was made through three-quarters of the tissue width before rotating the 
tissue 180
o 
and then cutting through three-quarters from the opposite side. This procedure 
was done for the entire length of the tissue and the tissue was gently spiralled to its full 
length. The ends of the zigzag tracheal strip were then cut below the pharynx and above the 
bronchial bifurcation and the remaining zigzag strip cut into two equal pieces. On each end of 
the two pieces, a cotton thread was fixed by passing a surgical needle with thread through the 
cartilage material taking care not to damage the muscle in the process. The tissues were 
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thereafter mounted in the isolated organ bath filled with 15 ml of KH solution at 37 
o
C. One 
end of the tissue was attached to the stainless steel hook (k) and the opposite end to the force 
displacement transducer (G). A 2 gram resting tension was applied to the tissue and the tissue 
was then allowed to equilibrate for 1 to 2 hours with washing at 15 min intervals with KH 
before it was exposed to various concentrations of the broncho-constricting mediators and 
plant extracts. 
 
5.3.2     Protocols 
5.3.2.1   Establishing concentration of agonist to use. 
To establish the concentration of agonist to use in this study, increasing serial concentrations 
of each agonist were injected into the bath. From the results a log dose response curve was 
obtained and from such curve the concentration of agonist giving responses of > 50 % < 100 
% was selected. Concentrations in the results section are those obtained in the 15 ml organ 
bath after injection of 0.1 ml of the solutions. 
5.3.2.2   Determining the relaxant effect of the plants on agonist-induced contraction 
To quantitate the tracheal smooth muscle relaxant effect of the two plant extracts, the trachea 
was contracted by injection of 0.1 ml volumes of histamine (1 mM), carbachol (1 µM) or 
potassium chloride (100 mM) into the bath. When stable contractions were achieved, 0.1 ml 
volumes of increasing concentrations of aqueous extracts of A. afra and L. leonurus (1, 3, 10, 
30 and 100 mg/ml) were added to the bath without washing in between injections, followed 
by a final 0.1 ml volume of isoprenaline (6.67x10
-6
). The magnitude of response on each 
injection was measured, recorded and displayed with the LabChart
® 
7 software. The degree of 
relaxation produced by each of the plant extract samples were calculated as a percentage of 
the full relaxation response obtained with the isoprenaline. A decrease in tone was considered 
to be a relaxant (bronchodilatory) effect and expressed as a positive percentage change. An 
increase in tone was considered as a contractile (bronchoconstriction) effect which was 
expressed as negative percentage change (Martin et al., 1994). For each plant, responses to 
four replicates of each concentration were obtained. No correction for the 15 ml bath volume 
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was made and relaxation versus concentration curves were elaborated and analysed to assess 
the smooth muscle relaxant effects of the two plant extracts. 
5.3.2.3   Establishing possible mechanism involved in the smooth muscle relaxant effect 
of both plants    
To determine the possible mechanism involved in the smooth muscle relaxant effect of both 
plants, the same procedure described in section 5.3.2.2 was followed, i.e. 0.1 ml solutions of 
aqueous A. afra and L. leonurus extracts (1- 30 mg/ml) were injected in the bath and left for 
20 min before cumulative concentrations of the agonist were introduced. The responses 
obtained after each injection were expressed as a percentage of the maximum contraction 
obtained per tissue and used to generate a dose response curve. For each plant four replicate 
dose response curves were obtained. 
 
5.4        Data analysis 
The experiments were done in triplicate (n=3). The plant concentration versus % relaxation 
curves were analysed using GraphPad
®
 Prism. The EC50 values were calculated by linear 
regression and compared to each other. All response data was expressed as mean ± S.E.M. 
The difference between means was determined by use of unpaired student- t test. Values were 
considered significant if the p value was less than 0.05. 
 
5.5        Results and Discussion  
5.5.1    Effect of L. leonurus and A. afra on trachea constricted with carbachol, KCL and 
histamine  
To determine whether A. afra and L. leonurus directly relaxes the pre-contracted airway 
smooth muscle, the isolated guinea-pig trachea was perfused with various concentrations (1 - 
100 mg/ml) of the aqueous extracts. L. leonurus and A. afra relaxed tracheal tissue pre-
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contracted with carbachol (1 µM), high potassium Krebs Henseleit solution (K 
+
 100 mM) 
and histamine (1 mM) in a dose-dependent manner (figure 5.4 and figure 5.5).  
The 100 mg/ml solutions of A. afra caused 93.8 ± 2.39 %, 91.5 ± 0.31 % and 88.5 ± 4.20 % 
relaxation of carbachol, histamine and KCL pre-contracted airway smooth muscle, 
respectively, while the 1 mg/ml solutions produced 1.25 ± 0.95 %, 4.0 ± 3.72 % and 8.4 ± 
4.61 % relaxation of carbachol, histamine and KCL induced contractions (figure 5.4). 
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Figure 5.4: Dose response curves of relaxation (%) caused by cumulative concentrations of 
A. afra (1-100 mg/ml) on isolated guinea pig trachea constricted with carbachol 
(1 µM), KCL (100 mM) and histamine (1 mM)  (n=4) 
 
For A. afra, the dose dependency of the bronchodilatory effect was similar for all three 
mediators of contraction. To compare the potency of A. afra on the 3 different mediators, the 
EC50 was used. EC50 is the concentration inducing 50 % relaxation of pre-contracted guinea 
pig tracheal muscle. The EC50 value of A. afra for relaxing carbachol, KCL and histamine 
induced contractions were 13.93, 19.88 and 15.47 mg/ml, respectively. Although the induced 
relaxations were very similar, A. afra was more effective in relaxing carbachol induced 
contractions compared to KCL (P = 0.0223) and histamine induced contraction (P = 0.0928), 
suggesting that relaxant activity of A. afra versus the three agonists could be categorized as 
follows:  carbachol > histamine > KCL  (i.e. 1 : 1. 11  : 1.43  EC50 value order). 
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Similar to A. afra, the bronchodilatory effect of L. leonurus was also dose dependant. The 
100 mg/ml solutions of L. leonurus induced 93.5 ± 2.18 % and 95.8 ± 2.93 % relaxation of 
the airway smooth muscle pre-contracted with carbachol and KCL, respectively, while the 1 
mg/ml and 3 mg/ml solutions caused 5.25 ± 2.10 % and 4 ± 2.03 % relaxation, respectively. 
On the histamine pre-contracted tissue, the 100 mg/ml solutions of L. leonurus caused 55.1 ± 
4.28 % and the 3 mg/ml solutions 2.29 ± 1.67 % relaxation of the pre-contracted trachea 
tissue while the 1 mg/ml dose produced 0 % relaxation (figure 5.5). The dose dependant 
effect of L. leonurus on carbachol and KCL induced contractions thus appeared to be 
quantitatively similar but substantially stronger than that against the histamine induced 
contractions.   
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Figure 5.5: Dose response curves of the relaxation (%) caused by cumulative concentrations 
of L. leonurus (1-100 mg/ml) on isolated guinea pig trachea contracted with 
carbachol (1 µM), KCL (100 mM) and histamine (1 mM)  (n=4) 
 
To compare the potency of L. leonurus on the different mediators, EC50 was calculated (table 
5.1). L. leonurus was significantly more effective in relaxing KCL induced contractions 
(EC50 value of 9.877 mg/ml), compared to carbachol (EC50 value of 29.74 mg/ml; P = 0. 
0010) and histamine-induced contractions (EC50 value of 94.76 mg/ml; P = 0. 0002). Overall, 
based on EC50 values, the relaxant activity of L. leonurus versus the three inducers of 
contraction (agonists) appear to be in 1:3:10 order or classified as follows: KCL > carbachol 
>> histamine. 
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Table 5.1: EC50 values of A. afra and L. leonurus 
induced relaxation of KCL, histamine and 
carbachol – induced contractions of the 
guinea pig tracheal muscle. 
Mediators A. afra L. leonurus 
 EC50 (mg/ml) EC50 (mg/ml) 
KCL 19.88 9.87 
Carbachol 13.93 29.34 
Histamine 15.47 94.76 
 
 
Interestingly, when the tissue was exposed to carbachol, a stable contraction obtained, 
thoroughly washed (to remove any traces of the agonist), and then exposed to doses of L. 
leonurus plant extract in the absence of carbachol, the muscle showed a complex reaction. At 
1 and 3 mg/ml L. leonurus produced, instead of the expected no response, a pronounced slow 
contractile response (figure 5.6, A).  However, doses ≥ 10 mg/ml L. leonurus injected 
immediately post carbachol washout produced no such contractile response (figure 5.6, B). 
When the 1 and 3 mg/ml doses of L. leonurus were followed by doses ≥ 10 mg/ml (figure 
5.6, C) the contractile responses were however antagonised. Contrary to these L. leonurus 
effects, A. afra extract at all concentrations injected (i.e. 1 to 100 mg/ml) elicited no response 
(i.e. no contraction) of the washed carbachol-exposed tissue. The reason(s) for these 
differences in effects between L. leonurus and A. afra is not clear but other researchers have 
observed similar biphasic effects e.g. with methanolic extract of Dichrostachys cinerea and 
aqueous extract of A. afra (Aworet-Samseny et al., 2011; Harris, 2002). It is possible that L. 
leonurus contains both active contractile and relaxant compounds. 
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Figure 5.6: Contraction induced by L. leonurus (1 mg/ml) on isolated guinea pig trachea after 
carbachol was thoroughly washed out, with full antagonism by 30 mg/ml L. 
leonurus. 
 
 
In summary, both A. afra and L. leonurus were clearly able to relax cholinergic, 
histaminergic and KCL induced contractions in a dose dependent manner. There were 
however subtle differences. For instance, at the doses studied, L. leonurus was more effective 
in inducing guinea pig trachea relaxation against KCL induced contractions (EC50 value 9.87 
mg/ml) than A. afra (EC50 value 19.88 mg/ml). On the other hand A. afra showed far more 
significant relaxant activity against carbachol (EC50 value of 13.93 mg/ml) and histamine 
(EC50 value of 15.47 mg/ml) than L. leonurus on carbachol (EC50 value 29.34 mg/ml) and 
histamine (EC50 value 94.76 mg/ml) induced tracheal relaxations, respectively. Nevertheless, 
in general, both L. leonurus and A. afra were effective antagonists against all three agonists 
which play a major part in asthma and thus have good potential as bronchodilators. There is 
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however also no other previous studies on these plants with which this present findings can 
be compared. 
 
It is possible that the similarity and subtle differences in the potencies of A. afra and L. 
leonurus versus the three broncho-constrictors used may be due to differences in chemical 
composition. In this study the flavonoid, especially luteolin content of the two extracts was 
quantified (Chapter 4). A. afra was found to contain significantly more (16.394 ± 0.884 µg 
total luteolin/mg FDAE) luteolin than L. leonurus (3.093 ± 0.531 µg total luteolin/mg 
FDAE). Despite the vast difference in luteolin levels between A. afra and L. leonurus, the 
bronchodilatory effects concerning the two were not significantly different with exception to 
histamine. An explanation could be that luteolin if responsible for the bronchodilatory effects 
is not the main constituent responsible for the observed relaxations. It is more likely that 
flavonoids found in the plants work in synergy to produce the observed responses i.e. luteolin 
and quercetin both found in A. afra have been implicated in trachea smooth muscle relaxation 
(Ko et al., 2004).  In addition, synergy between flavonoids and other chemical compounds 
also cannot be excluded as a further explanation for the present finding. Clearly a more 
detailed chemical profile of the extracts will be required to fully answer this question.  
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5.5.2   Identification of possible mechanism(s) of action involved in the inhibitory     
effects of L. leonurus and A. afra. 
To determine the possible or predominant mechanisms involved, the tissue was exposed to 
cumulative doses of carbachol (0.1-10 µM), histamine (0.1-10 mM) and KCL (20-100 mM) 
in the absence and presence of  L. leonurus and A. afra (1, 30 and 100 mg/ml). The results 
obtained are summarised in figures 5.7 and 5.8 below. 
 
 
Figure 5.7: Carbachol (A), histamine (B) and KCL (C) induced contraction (%) versus 
log concentration curves in the absence and presence of 1, 30 and 100 
mg/ml L. leonurus. (n=4) 
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Figure 5.8: Carbachol (A), histamine (B) and KCL (C) induced contraction (%) versus 
log concentration curves in the absence and presence of 1, 30 and 100 
mg/ml A. afra. (n=4) 
 
At the doses used, L. leonurus inhibited the contractions of all three constrictors. At 1 mg/ml 
its action appeared to be competitive i.e. the carbachol, histamine and KCL graphs were 
displaced to the right and magnitudes of maximal response as well as the concentrations 
producing maximal response were not altered (Gilani et al., 2008). At doses of 30 and 100 
mg/ml its action appeared to be non-competitive i.e. there was a non-parallel shift of the 
carbachol, histamine and KCL graphs with suppression of the maximum effect (Gilani et al., 
2008; Khan et al., 2008). At a dose of 100 mg/ml L. leonurus, it was impossible to recreate 
the LDRC‟s using very high doses of carbachol, histamine and KCL. Collectively, these 
results clearly indicate that L. leonurus affected the mediator induced contractions in similar 
 
 
 
 
67 
 
ways that and do not suggest a more prominent involvement of K
+ 
channels, above histaminic 
and cholinergic receptors, in the relaxant effect of L. leonurus. 
 
Likewise, A. afra also antagonised the contractions induced by all three constrictors in a 
similar manner. In the presence of 1 mg/ml A. afra, carbachol and KCL log dose response 
curves were displaced to the right with no alteration of concentration and maximal response 
(Figure 5.8). However, there was no rightward shift (instead an evident slight parallel 
leftward shift) of the histamine LDRC in the presence of 1 mg/ml A. afra. The mechanism 
involved in the inhibition of histamine-induced contractions was thus most likely non-
competitive although a competitive histamine receptor mediated mechanism cannot be ruled 
out. The 100 mg/ml dose of A. afra however caused significant non-parallel shifts with 
suppression of the maximum effect of the LDRC for all three agonists, strongly suggesting a 
non-competitive inhibitory mechanism for the plant. As for A. afra, these results also suggest 
a possible involvement of K
+ 
channels, histaminic as well as cholinergic receptors in the 
relaxant effect of A. afra, and also do not suggest a more prominent involvement of K
+ 
channels, above histaminic and cholinergic receptors, in the relaxant effect of this plant. 
 
It was hypothesised that KATP channels would be the significant mechanism responsible for 
the smooth muscle relaxant actions of both A. afra and L. leonurus. KATP channel activators, 
as typified by cromakalim exert their actions by binding to the (sulphonylurea) receptor 
subunit inducing a conformational change in this subunit, leading to an increased open 
probability of the K
+ 
channel pore. By virtue of such a mechanism, these drugs are able to 
hyperpolarize the smooth muscle and cause a relaxant response (Pelaia et al., 2002). 
However, based on the above results, this hypothesis  looks very unlikely since KATP channel 
activators  are known to also show a poor inhibitory effect on contractile responses induced 
by cholinergic agonists in guinea-pig trachea (Pelaia et al., 2002) and in the present study A. 
afra and L. leonurus showed good inhibitory effects against the cholinergic agonist 
(carbachol) used, strongly suggesting that it is very unlikely that KATP channels are the 
predominant mechanism responsible for the actions of A. afra and L. Leonurus.  
Unfortunately, specific inhibitors (e.g. glibenclamide) of such channels were not used in this 
study to fully challenge this hypothesis. 
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Although not focussed on in this study phosphodiesterase inhibition may also possibly play a 
prominent role in the inhibitory effects of A. afra and L. leonurus on the agonist- induced 
contractions. Histamine, and to a lesser extent carbachol, stimulate cyclic nucleotide 
phosphodiesterase which catalyse the hydrolysis and inactivation of cAMP leading to 
contraction of tracheal smooth muscle (Krymskaya and Panettieri, 2007; Turner et al., 1994). 
Phosphodiesterase (PDE) 3 and 4 inhibitors are potent relaxants of guinea pig trachea pre-
contracted with histamine and carbachol (Krymskaya and Panettieri, 2007). Luteolin 
(contained in both plants) inhibits cyclic adenosine monophosphate (cAMP) - and cyclic 
guanosine monophosphate (cGMP)-phosphodiesterases (PDE), with the subsequent increase 
of these two cyclic nucleotides which causes smooth muscle relaxation (Ko et al., 2005). In 
addition, quercetin inhibits phosphodiesterase 4 (specifically PDE4D) as well as 
phospholipase Cβ (or PLCβ), another PDE enzyme,  preventing the degradation of cAMP 
which in turn binds to and activate  protein kinase A (PKA) which in turn induces smooth 
relaxation by (1) increasing Ca
2+
 -sequestration or extraction, (2) preventing Ca
2+ 
influx, (3) 
hyperpolarizing cell membranes by activating Na
+
, K
+ 
- ATPase or opening of large 
conductance K
+
 channels, or (4) direct modulation of contractile protein  (Ko et al., 2004; 
Spina et al., 1998; Townsend and Emala, 2013). Therefore phosphodiesterase inhibition 
(instead of KATP channels mediation) may possibly better explain the inhibitory effects of A. 
afra and L. leonurus on agonist- induced contractions in the present study. Finally, 
differences in the variety plus levels of other compounds (i.e. besides flavonoids) also present 
in the two plant extracts would also need to be elucidated if a correct full final explanation of 
the present data is to be made.  
5.6        Conclusion 
Overall, the findings obtained indicate that A. afra and L. leonurus were able to relax 
cholinergic, histaminergic as well as KCL induced contractions in a dose dependent manner. 
Maximal or near maximal reversal of the agonist induced contractions were obtained with the 
plant concentrations used in this study. In general A. afra was a stronger tracheal smooth 
muscle relaxant, it effectively relaxed KCL and histamine induced tracheal contractions more 
than L. leonurus. The mechanism for the antagonism was complex, being competitive at low 
doses of the plant extracts but non- competitive at high doses of the extracts. KATP channel 
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activation clearly did not appear to be a predominant mechanism involved in the relaxant 
activities of both A. afra and L. leonurus, rather more than one mechanism of action possibly 
reflective of differences in active ingredients seems to be involved.  
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Chapter 6 
Conclusions and Recommendations 
 
The overall aim of this study was to determine whether Artemisia afra and Leonotis leonurus 
produce their anti-asthmatic effects in and by similar means, and the specific objectives were 
to determine and compare the profiles and levels of flavonoids in Artemisia afra and Leonotis 
leonurus, compare the respiratory smooth muscle relaxant effects of freeze-dried aqueous 
extracts of Artemisia afra and Leonotis leonurus and investigate whether KATP - channel 
activation is one possible mechanism of action that can explain the effect obtained during  
traditional use of these two plants. It was hypothesized that the flavonoid profile and levels of 
Artemisia afra would be greater than that of Leonotis leonurus, Artemisia afra would be more 
potent i.e. have greater respiratory muscle relaxant effect than Leonotis leonurus and, finally, 
that A. afra and L. leonurus will inhibit K
+
 -induced (i.e. KATP channel mediated) contractions 
in a superior manner than carbachol and histamine induced contractions. 
From the results obtained the following conclusions could be drawn: 
1. The freeze-dried aqueous extract of A. afra and L. leonurus are different in flavonoid 
profile and levels. A. afra had higher levels of the marker luteolin whereas L. leonurus 
contained greater number of flavonoid profile and higher percentage of luteolin 
conjugates. 
 
2. A. afra is more potent at relaxing guinea pig trachea smooth muscle than L. leonurus. 
Although L. leonurus was more effective at relaxing KCL induced contractions, A. 
afra showed a greater relaxation on carbachol and histamine induced contractions of 
the tracheal smooth muscle. It is likely that more than one active compound is 
responsible or a common pathway shared by the agonists (carbachol, histamine and 
KCL) used is involved in the trachea smooth muscle relaxation of the two plants.  
 
3. Both A. afra and L. leonurus relaxed KCL induced contractions, but they also relaxed 
histamine and carbachol. Thus inhibition via KATP channels is likely not a prominent   
mechanism of relaxation for both   A. afra and L. leonurus FDAE. 
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Overall the results obtained confirmed that, aqueous solutions of A. afra and L. leonurus, as 
used in local traditional practice, have potent bronchodilator activity that could be of use in 
the treatment of asthma. 
The study had a few limitations. Unfortunately, KATP channel inhibitors such as 
glibenclamide were not used in this study to fully investigate KATP channel involvement in 
the smooth muscle relaxant effect of the two plants. Moreover, it would have been 
worthwhile to assess luteolin relaxant effect on the guinea pig trachea. This would have given 
a much more elaborate indication of whether luteolin is indeed involved in smooth muscle 
relaxation induced by A. afra and L. leonurus. 
The results also highlighted several areas for further research. Firstly, further studies are 
required to exactly identify the compounds responsible for the relaxant activities of the two 
plants. It may be useful to focus on flavonoids present in the plants for the first investigations. 
But at least greater detail on the variety plus levels of different individual flavonoids might 
prove useful. Secondly, other mechanism(s) of action should also be investigated. For 
instance, it would be interesting to ascertain the role, if any, of PDE 4 inhibitory activity, 
which has already been suggested for L. leonurus (Mulubwe, 2004), intracellular Ca
+ 
regulation and the Ca
+
 activated potassium channels. Definitive studies on the mechanism 
would however be best explored after active compounds have been identified and isolated. 
Lastly, an actual assessment of the relative chemical safety the two plants, a prelude to 
chemical efficacy study in asthmatics may be well warranted. From such studies, more 
effective anti-asthma treatments may arise and it may also guide to more effective utilization 
of these plants. 
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Appendix 1 
 
 
Appendix  1:  Trace of relaxation (g force) caused by cumulative concentrations of A. afra on isolated guinea 
pig trachea constricted with carbachol. 
 
  
 
 
 
 
 
 
 
 
 
88 
 
 
 
 
 
Appendix 2 
 
 
Appendix  2: Trace of relaxation (g force) caused by cumulative concentrations of L. leonurus on isolated 
guinea pig trachea constricted with carbachol. 
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Appendix 3 
 
 
Appendix  3:  Trace of relaxation (g force) caused by cumulative concentrations of A. afra on isolated guinea 
pig trachea constricted with histamine. 
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Appendix 4 
 
 
Appendix  4: Trace of relaxation (g force) caused by cumulative concentrations of L. leonurus on isolated 
guinea pig trachea constricted with histamine. 
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Appendix 5 
 
 
Appendix  5: Trace of relaxation (g force) caused by cumulative concentrations of A .afra on isolated guinea 
pig trachea constricted with KCL. 
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Appendix 6 
 
 
Appendix  6: Trace of relaxation (g force) caused by cumulative concentrations of L. leonurus on isolated 
guinea pig trachea constricted with KCL. 
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